CA1175816A - 1-N-(.alpha.-HYDROXY-.omega.-AMINOALKANOYL) DERIVATIVES OF 5, 3',4'-TRIDEOXY- OR 5,3',4'-TRIDEOXY-6'-N-METHYL- OR 5,3',4',6"-TETRADEOXY-KANAMYCIN B AND PRODUCTION THEREOF - Google Patents

Abstract

New 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl) derivatives of 5,3',4'-trideoxy- or 5,3',4'-trideoxy-6'-N-methyl-or 5,3',4',6"-tetradeoxy-kanamycin B and production thereof ABSTRACT OF THE DISCLOSURE
New antibacterial compounds are provided, including a 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxykanamycin B; a 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4',6"-tetra-deoxykanamycin B; and a 1-N-(a-hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxy-6'-N-methylkanamycin B; as well as 5,3',4',6"-tetradeoxykanamycin B and 5,3',4'-trideoxy-6'-N-methylkanamycin B.

Description

1 ~S~16 BACKGROUND OF THE INVENTION
Field of the invention This invention relates to new semi-synthetic aminoglycosidic antibiotics, including a 1-N-[~-hydroxy-~-aminoalkanoyl]-5,3',4'-trideoxykanamycin B; l-N-[~-hydroxy-~-aminoalkanoyl]-5,3',4',6"-tetradeoxykanamycin B
and 5,3',4',6"-tetradeoxykanamycin B as well as a l-N-[~-hydroxy-~-aminoalkanoyl]-5,3',4'-trideoxy-6'-N-methyl-kanamycin B and 5,3',4'-trideoxy-6'-N-methylkanamycin B
which are each the new compound useful as antibacterial agent. This invention also relates to processes for the production of these new compounds. This invention further relates to an antibacterial composition comprising one of these new compounds as the active ingredient.
; 15 Description of the prlor art Dibekacin, namely 3',4'-dideoxy~anamycin B was semi-synthetically produced from kanamycin B by the present inventors (see Japanese patent publication No. 7595/75; Japanese patent No. 794,612j U.S. patent No. 3,753,973). Dibekacin has been used extensively in therapeutic treatment of various bacterial in~ecti.ons as a chemotherapeutic agent which is active against the kanamycin-sensitive bacteria and also against various kanamycin-resistant bacteria. We, the present inventors, produced semi-synthetlcally habekacin, namely 1-N-(L-4-amino~2-hydroxybutyryl)-dibekacin which is a I i75~16 chemotherapeutic agent effective against dibekacin-resistant bacteria ~see Japanese patent publication No. 33,629/77;
U.S. patent No. 4,107,424). We also produced semi-synthe-~ tically a l-N-ra-hydroxy-~-amino-alkanoyl~-6'-N-methyldi-bekacin which has been found to be highly active against various strains of bacteria (U.K patent No. 1,475,481;
U.S. patent No. 4,147,861~. In our further researches, we produced synthetically the 6"-deoxy or 4",6"-dideoxy deriva-tives of dibekacin and habekacin, i.e., l-N-~L-4-amino-2-hydroxy~utyryl]-dibekacin, respectively. Furthermore, we have found that these 6" deoxy derivatives and 4",6"-dideoxy derivatives o~ dibekacin or habekacin exhibit not only a low o~o-toxicIty but also show an antibacterial activity as hi~h as that of dibekacin or habekacin tpublished U.K.
patent application 2,058,774 A).
We also produced 5,3',4'-trideoxykanamycin B as a further deox~ derivative of dibekacin ~Japanese Journa of Antibiotics, 32, S-178, (1979)). However, it has been found that 5,3',4'-trideoxykanamycin B is less active than dibekacin.
It may be added that we further have produced some deoxy derivatives of l-N-(L-4-amino-2-hydroxybutyryl)-kanamycin A (i.e. amikacin~, includin~ 3'-deoxyamikacin mah/ ~ - 2 -, ~ 175~6 (U~S. patent No. 4,104,372), 3',4'-dideoxyamikacin (publisned U.R. patent application 2,043,034 A), 6"-deoxyamikacin, 4",6"-di.deoxyamikacin~ 3',4',4",6"-tetradeoxyamikacin and 3',4' r 6 ~'~ trideoxyamikacin, as well as 3l,6"-dideoxyamikacin, 5,3'-dideoxyamikacin and 5,3',6"-trideoxyamikacin, which all have a low acute toxicity and a lo~ oto-toxicity while exhibiting a useful antibacterial activity as high as that of amikacin.

SUMMARY OF THE INVENTION
In further development of our researches on the . deoxy derivatives of dibekacin or habekacin, we have now : succeeded to produce a new compound, 5,3',4',6"~tetradeoxy-kanamycin B which has been found to be significantly act;ve a~ainst some kinds of hacteria, though the 5,3',4'-triaeoxy-kanamycin B exhibits no useful antibacterial activity. We have also succeeded to.produce a new-compound, 5,3',4'-. trïdeoxy-6'-N-methylkanamycin B which also exhibits an anti-bacterial actiVity hi.gher than that of the 5,3',4'-trideoxy-kanamycin B. especially~against some resistant strains. In an attempt to produce such new mab/~?~ h I ~.7~`816 ., .

derivatives of 5,3',4'-trideoxykanamycin B, 5,3',4',6"-tetradeoxykanamycin B or 5,3',4'-trideoxy-6'-N-methyl-kanamycin B which will have improved antibacterial activity, we have now synthetized new l-N-[N-hydroxy-~-aminoalkanoyl] derivatives of these deoxykanamycins B by acylating the l-amino group of the deoxykanamycin B with an N-hydroxy-~-aminoalkanoic acid. Then, we have discovered that the resultant new l-N-[N-hydroxy-~-aminoalkanoyl]
derivatives of 5,3',4'-trideoxykanamycin B, 5,3',4'-trideoxy-6'-N-methylkanamycin B, and 5,3',4',6"-tetra-deoxykanamycin B are very much active against kanamycin-sensitive and kanamycin-resistant bacteria and also exhibit a high antibacterial activity against a wide range of bacteria.
According to the first, most generic aspect of this invention, therefore, there is provided as the new compound a l-N-[~-hydroxy-~-aminoalkanoyl]-5,3',4'-trideoxy- or ; l-N-[~-hydroxy-~-aminoalkanoyl]-5,3' 5 4'-trideoxy-6'-N-~ methylkanamycin B or 5,3',4'-trideoxy-6'-N-methylkanamycin : 20 B or a l-N-[N-hydroxy-~-aminoalkanoyl]-5,3'~4',6"-tetra~
deoxykanamycin B or 5,3',4',6"-tetradeoxykanamycin B
represent0d by the ~ormula (I) . . .

. ' .

R \6"
HO ~ ~ O \ H2N ~, ~ ' H N ~ ~~~~~~ ~" ~ ~' ~ (I) RlHN _ ~ H2 wherein R is a hydroxyl group or a hydrogen atom, Rl is a hydrogen atom or an a-hydroxy-~-aminoalkanoyl group of formula : ~ f ; OH
where n is an integer of 1, 2 or 3, and R2 is a hydrogen atom or a methyl group, provided that R2 is not the methyl :: group when R is the hydrogen atom, or a pharmaceutically :
acceptable acid-add~tion salt of said compound.

According to the first preferred embodiment of the : first aspect invention, there is provided a new compound which belongs to the new compound o~ the above formula (I) :
and is a 1-N-[a-hydroxy-~-aminoalkanoyl3-5,3',4'-trideoxy-: kanamycln B or 1-N~ hydroxy-~-aminoalkanoyl]-5,3',4',6"-tetradeoxykanamycin B represented by the formula (II) .

: "~

~ , , . . , :
: , :

.

6~

4 ~'H2 (II) ~ NH 2 CO

CHOH
~CH2)nNH2 wherein R is a hydroxyl group or a hydrogen atom and n is an integer of 1, 2 or 3 and wherein R is the hydroxyl group when the compound of the formula (II) is a l-N-[a-hydroxyl-~-aminoalkanoyl]-5,3',4'-trideoxykanamycin B but R is the hydrogen atom when the compound of the formula (II) is a l-N-[a-hydroxy-~-aminoalkanoyl]-5,3',4',6"-tetradeoxy-kanamycin B, or a pharmaceutically acceptable acid-addition salt of the compound (II).
Acco.rding to the second preferred embodiment of the first aspect invention, there is provided a new compound which belongs to the compound of the formula (I) and is 5,3',4',6'~-tetradeoxykanamycin B represented by the formula (III) . .

~ li75~16 6~ 2 4~ CH3 / o H2N ~ 4, HO ~ 1" 0 ~ NH2(III) or a pharmaceutically acceptable acid-addition salt of the compound (III).
The physico-chemical and biological properties of the new compounds of the formulae (II) and (III) according to the first and second preferred embodiments of the first aspect invention are as follows:-(1) 1-N-[(S)~4-amino-2-hydroxybutyryl]-5,3',4'-trideoxykanamycin B monocarbonate monohydrate is a substance in the form of a colorless powder decomposing at 163-166C
and showing a specific optical rotation [~326 = +87 (c 1, water). Its elemental analysis is coincident with the theore~ical values of C22H44N609 H2C03 H20 (C 44.80%, H 7.85%, N 13.63%). This substance gives a single spot (positive to nlnhydrin) at Rf 0.05 and at Rf 0.0~ ln a thin layer chromatography on silica gel developed with butanol-ethanol-chloroform-17% aqueous ammonia (4:5:2:5 by volume) and with chloroform-methanol-conc. aqueous ammonia-water (1:4:2:1 by volum~)as the development solvent, respectively.
29 (2) 1-N~[(RS)-3-amino-2 hydroxypropionyl]-5,3l,4'-trideoxykanamycin B monocarbonate is a substance in the -` ` 1 17S816 form of a colorless powder decomposing at 113-116C ~and showing a specific optical rotatlon Ca]27 = ~120 (c 1,~
water). Its elemental ana~lysis ls coincident with t~he theoretical value~s ~G21H42N69 ~2C3 ( N 13.63%~. This~substance gives a single spot ;(positive~
to ninhydrin) at~ Rf 0.12~and at~Rf 0.35 in the above~
mentioned thin~layer~chromatography~on sllloa gel developed with butanol-ethanol-chloroform-171 aqueous;~ammonia~(~4~:~5:2~:;5 by~volume) and with~chloroform-methanol-conc~.~aqueous~
lO ~ ammonia-water~(l 4:2~ by~volume~) as the development solvent, respect~ively.
(3) 1-N~-~;(S);-4-amino-~2-hydroxybutyr~1]-5~,3~ 4'~,~6~"-t~etra~
deoxykanamyoi;n B~dicarbanate ;i~s~a substance~l~n the~orm~;o~

a~colorless~powder~ decomposlng~at~ 31-1~35C and showine~a~
15~ speolfic opti~cal~rot n ~[~a]27~ +90 (c l,~wat ~ s elemental~analysi~s~is~coincident~with~t~he~theore~ic l~

values;o~f~C~22H~4~N60 H co3~c~44~7l~%~ H~ 5o%~ N .~0 `-~
This~s~ub~s~tance~g ~ ~ e;apot~(posi~t~i e bo~
at~R~ 0~.~07;:and~a~ Rf~0.;23~in~t~he~abov~-~ ntioned~th 20~ ohromatography an silica gel developedwithbutanol ~ ~ a ohloro~orm-17g~aqueous ammonla (4:5:2:~5`by volume) and~
wlth chloroform-methanol-conc. aqueous am~on~a-wate~r~
4:2:1 by volumé)~aa the; development solvent, respeotlvely.
(4) 5,3',4',6;~-tetradeoxykanamyoin B dicarb~onate ~monohydrate is~ a sub;s`tance~in the ~orm o~ a colorléss~
powder decompo;sing~at~l28-136C~and~s~howing~a speoi~io optical rotation [~]D3 = +102 (c 1, water). Its elemental analysis is coincident with the theoretical values of C18H37N506 2H2C03 H20 (C 42.77%, II 7.72~, N 12-47%)- This substance gives a single spot (positive to ninhydrin) at Rf 0.1l2 and at Rf o.56 in the above-mentioned thin layer chromatography on silica gel developed with butanol-ethanol-chloroform-17% aqueous ammonia (4:5:2:5 by volume) and with chloroform-methanol-conc. aqueous ammonia-water (1:4:2:1 by volume) as the development solvent, respectively.
The minimum inhibitory concentration (mcg/ml) of [(S)-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxykanamycin ~ B (abbreviated as AHB-trideoxyKMB), l-N-[(RS)-3-amino-2-; hydroxyprapionyl]-5,3',4'-trideoxykanamycin B (abbreviated as AHP-trideoxy-KMB) and l-N-[(S)-4-amino-2-hydroxybutyryl~-5,3',4',6"-tetradeoxykanamycin B (abbreviated as AHB-tetradeoxyKMB) of the formula (II) according to this invention as well as of the new compound ~,3',4',6"-tetradeoxykanamycin B ~abbreviated as tetradeoxyKMB) of the formula (III) according to this invention against various microorganisms were determined according to serial dilution method on a nutrlent agar medium at 37C, the estimation being made a~ter 18 hours incubation. For comparison purpose, the minimum inhibitory concentrations of ~abekacin were also determined in the same manner- as stated above.
The antibacterial spectra of these new and known substances are shown in Table l below.

., I
,:
' :

~ ~75~16 _ _ ...... _~

X
. O ~ O L~ ~ ~ O O ~ CO L~
.~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ,, O ~O ~D O O O O O ~ O ~O ~ O
~ V V V r-l E~ ~ ~\
.
~, r~
~1 C~ ~ ~ O ~ CO ~D ~D O O O
C~ ~ ~ ~ ~ ~ U~
C) ~ ~rl O O O O ~ ,i o o o ,i o ~ ~ o ~C~ V V V V
~ ~, H ~d .
O O OC 0~ GO O O O O~ O C~
~-OOoo~oooooooOoO
O V V V V V V
. . . ... ~ .. _ _____ ._ .... _ I m O O tX~ 00 0 0 0 0;:~O
~:; t'l ~ I L~ L~
P~.
~1 I ~q O O O O ~D O O O O O O ~ ~ O r~
¢ ~ V v v V V ~1 P . ~ ~
E~ I ~
o oa~ o o o oo o co o~
~1 ~ ~ ~ (~ L~
~ OOOO~OOOOOOOOOO
¢ ~ V V V V V ~l _ .__ __ ~ __ . ____ aO~ ~
~ ~ U~
P~ ~ r~ cq Lr\ ~I Et o~
a~ '!i ~ I ¢
O ~ ~ ~ r-i r~ ~ t~ Lt~
~ U~ ¢ ~rl ~ O ~ r;
u~ E3 ¢ ~1 ~ r-l ~rl El u~ O H
Ul ~ O C~
.~ a) ~ H ~ H
S ~ ~ bO 2 H ~r~ ¢ a~
bO ~ ~ p c~ r~
o ~ rl ~ ~ o ~::
c) ~ a~ ~ P ~ ~, cq ~ rl ~d O o o ~ rl E-l C) C) ~1 a~ ~:
o e : o c) u~ u~u~ ;n ~ c r ~ r-l O ~ V ~rl h P~ ~Ir-l r-l r-l ~ h O ~r1 r-lr-l r-l r-l ,9 : e ~ ~ r I
: _ - ~ m a: m m I ~7~6 . .

L~ Lr~ L~ L~
L~ L~ ~U ~ ~ ~ L~
~) ~ I tD O O O ~D O ~C) L~ ~1 0 N
r-l ~1 0 o o O ~I o r I
r-l r-l~1 ~1 ~1 A A
_. ~

L~ ~ Ll~ ~ ~Y7 ~ L
Ll~ ~ ~ ~ ~ ~ ~ ~ ~ ~ L~ ~ L~ ~ Lf~
.
~1 . _. __ __._ .

.
O O ~ ~ O ~ O O O ~ O O O

-- _, . ._. _ _ .. _ . _. ._ _ _ L~ ~ L~L~ L~ ~ Lt~ Lr~ L
.

.
C-- Lf~ L~\ 15~ Lr~ ~1 ~ t~ E-- Ln 1~ ~ C`- ~I r~
...............
O r-l r-l r-l r-l ~ O O O ~1 0 0 0 (~
_ , . _ ~
o~
~; L~-~ L~
p~ p~ ~ ~ ~
I O~ OO O ~ ~ O O
r~ NtY~ r~rl O O O 1~: 0 ~ rl ~1~O~D^=t ~ ~ O~a~ o ~Ir~1 r l N(~I ~U 1~ 0 H r l Lr~ N
V ~ N
L~
~I ~ N~I N N N ~ O N Ll~ O
~1~Ir~l r-lr-l r~l r~l 1~ ~O r~l ~\~ tt) ~I) I I II I ¦ ¦ ~ rl td ~ .rl r l O =
C~
P~ U~
~d ~d ~
C) rl ~rl a) ~1 rl r~l bO
~ ~ rl Ul r l ,~
~1 ~ Ul . , ~ ~7~16 _ ~o U~
1~ N N L~ -i 0 L~ O O O O O ~ L~ O
N ~1 ~I N O N O O U~ O O ~J O
~ ~ ~ ~ ~1 ~1 A A ~ ~\
.. ~ ~
L~ D ~ 00 N N Lf~ 1 N
.
~O ~) ~1 ~ O O N O OO IS~ O t~) ~) ~O
Ir~ O 1 A
.
~ O 00 ~ ~
L~ N ~-!
o ~ .~ ~o U~ ~ ~ o ~: N N N Ot~ N N

, ... . .
~ Lr~
C~l Nl N 1 ~O O~D O ~ ~ Lr~ O ~ L~ O
O ~~ ~U
A
_ .. _ __ .. ..
LS~ a~
~1 ~ ~1 ~ L~ ~ ~ ~1 . . . . . . . . . . .
L~~ O Lr~ O ~ ~ ~ O
~I N N Or-l ~1 1-l . . ____ _ ___.
::
r~ r-l r l .
r l ~ (rl O O~
.~ .~ ¢ æ ~
C~ ~O
r l W ~J
rl 0~ ~ ~0 tq :~ r l ~D d r~ 1 0 ~ r-l I rl ~ Z æ ~q ~
U~ ) O C!l C~ ~ rl rl ~ rl a) ~0 bO
4 rl )~ rl rl C~ r-l r~
~J rl ~ au rl h ~ U~ cr~
X ~ ~ ~ td bO bO c) P~ ~ (d ~ w ~ ~ ~ ~
r l O ~1 ~ ~ ~ O
4~ U~ ::1 rl rl I
td ~ r-l r~ t~ O
r I r~ ta U~ rl rl r~ i r-l r l ~ ~ ~ ~ d ~ O
~ a) O O O O aJ ~ ~d 1 rl r/
rl rl r-l ~ O O O ~ h ~ O O
~ u~ u~ u~

- 13 - ~ ~ ~58 1 6 L~
U~ ~ o Lr~ o o o o ~ o ~1 0 ~ Lr~ O O O ~ O
A A A A A
_ _~

L
.
~O ~O Lr\ L~ ~ O ~ O
~1 ~ ~ N O O
A

~ U~
L~ ~ ~ ~ U~ ~ ~1 .
7 0 ~O ~ O O ~ O
~1 0 r I ~1 0 0 _ . . . _ _ _ _ _ _ ___ _ _I
L~ ~
N r~
.
~D ~ O tYl ~ ~ ~O O ~ O
L~ ~ ~ O O
A

Ll~ O
L~
.
~O ~ L~ D ~ ~ O ~ O
I O O
~1 1-A A

~ L~ O ~
D~ a~
I ~ Z
z a~ I ~1 U~ I ~
~ m ~u ~ x ~
~ rl o o ~
~ ~ bO O

cq ~ C~
~ P C' o P~ o o o ~r o o ~d c _ : e e ca o ~ tq _ _ _. _ _ 1 4 - ~ 3 75 8 ~ ~

According to the third preferred embodiment of the first aspect inventlon, there is provided a new compound which belongs to the compound of the formula (I) and is a 1-N-[a-hydroxy-~-aminoalkanoyl]-5~3',4'-trideoxy-6'-N-methylkanamycin B represented by the formula (IV) HO 6"

~1" H2~ ~, 3...... OH I 6 4 5' HCH3 (IV) HN ~ NH2 CO

CHOH
(CH2)nNH2 wherein n is an integer of 1, 2 or 3, or a pharmaceutically acceptable acid-addition salt of the compound (IV).
According to the fourth preferred embodiment of the first aspect invention, there is further prov1ded a new compound which belongs to the compound of the formula (I) and is 5,3'~4'-trideoxy-6'-N-methylkanamycin B represented by the formula (V) ' .

~ 1758IB

6"
HO ~ 2' 4 ~ \ X2N~

H2N~llt ~ (V) o/ ~ NHcH3 H2N --~'~ NH2 or a pharmaceutically acceptable acid-addition salt of the compound (V).
The physico-chemical and biological properties o~
`the new compounds of the formulae (IV) and (V) according to the third and fourth preferred embodiment of the first aspect invention are as follows:-(5) l~N-[(S)-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxy-6'-N~methylkanamycin B monocarbonate is a substance in the form of a colorless powder decomposing at 162-165C and showing a specific optical rotation [a]22 = ~88 (c 1, water). Its elemental analysis is coincident with the theoretical values of C23H46N6O~ H2CO3 (C 47.05%, H 7.~0%, N 13.72%). This substance gives a single spot (positive to ninhydrin) at Rf 0.05 and at Rf o . o8 ln a thin layer chromatography on silica gel developed with butanol-ethanol-chlorof'orm-17% aqueous ammonia (4:5:2:5 by volume) and with chloroform-methanol-conc.
aqueous ammonia-water (1:4:2:1 by volume) as the develop-ment solvent, respectively.

. .

1 ~5~1 (6) 1-N-[(RS)-3-amino-2-hydroxypropionyl]-5,3',4'-trideoxy-6'-N-methylkanamycin B monocarbonate monohydrate is a substance in the ~orm of a colorless powder decom-posing at 162-164C and showing a speci~ic option rotation [~]D3 = ~80 (c 0.5, water). Its elemental analysis is coincident with the theoretical values of C22H44N6Og-H2CO3-H20 (C 44.80%, H 7.85%, N 13.62%). This substance gives a single spot (positive to ninhydrin) at Rf 0.05 and at Rf 0.14 in the above-mentioned thin layer chromatography on silica gel developed with butanol-ethanol-chloroform-17%
aqueous amrnonia (4:5:2:5 by volume) and with chloroform-methanol-conc. aqueous ammonia-water (1:4:2:1 by volume) as the development solvent, respectively.
(7) 1-N-~(S)-5-amino-2-hydroxyvaleryl]-5~3',4'-trideoxy-6'-N-methylkanamycin B monocarbonate monohydrate is a substance in the form of a colorless powder decom-posing at 163-166C and showing a specific optical rotation ~]D3 = ~84 (c 0.5, water). Its elemental analysis is coincident with the theoretical values of C24H48N6O9 H2C03 H2O (C 46.57%, H 8.13~, N 13.03%). This substance gives a single spot (positive to ninhydrin) at Rf 0.03 and at Rf o . o8 ln the above-mentioned thin layer chromatography on silica gel developed with butanol-ethanol-chloroform-17%
aqueous ammonia (4:5:2:5 by volume) and with chloroform-methanol-conc. aqueous ammonla-water (1:4:2:1 by volume) as the development solvent, respectively.

,. , ~ .. .

~ ~5~1~

(8) 5,3',4'-Trideoxy-6~-N-methylkanamycin B mono-carbonate monohydrate is a substance in the form of a colorless powder decomposing at 137-140C and showing a specific optical rotation [~]22 - +66 (c 1, water). Its elemental analysis is coincident with the theoretical ClgH39N507 H2C03 H20 (C 45.36%, H 8.18%, N 13 23%) This substance gives a single spot (positive to ninhydrin) at Rf 0.22 and at Rf 0.49 in the above-mentioned thin layer chromatography on silica gel developed with butanol-ethanol chloroform-17% aqueous ammonia (4:5-2:5 by volume) and with chloroform-methanol-conc. aq~eous ammonia-water (1:4:2:1 by volume) as the development solvent, respectively.
The minimum inhibitory concentrations (mcg/ml) of l-N-[(S~-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxy-6'-N-methylkanamycin B (abbreviated as AHB-trideoxyMKMB), l~N-[(RS)-3-amino-2-hydroxypropionyl]-5,3',47-trideoxy-6'-N-methylkanamycin B (abbreviated as AHP-trideoxyMKMB) and l-N-[(S)-5-amino-2-hydroxyvaleryl]-5,3',4'-trldeoxy-6'-N-methylkanamycin B (abbreviated as AHV-trideoxyMKMB) of the formula (IV) according to this invention as well as of the new compound $,3',4'-trideoxy-6'-N-methylkanamycin B (abbrevlated as trideoxyMKMB) of the ~ormula (V) according to this invention against various mlcroorganisms were determined according to serial dilution method on a nutrient agar medium at 37C, the estimation being made after 18 hours incubation. For comparison purpose, the 1 ~75~1 minimum inhibitory concentrations of l-N-[(S)-4-amino-2-hydroxybutyryl~-3',4'-dideoxykanamycin B (ie. habekacin) were also determined in the same manner as stated above.
The antibacterial spectra of these new and known compounds are shown in Table 2 below.

, , _ ~

~C ~ L~ co O ~
O U~ J ~ N 1O . ~ . . . . . . . .
~ m ~ O u~ ~D O u~ O O O ~ ~O ~ ~ O ~
~ ~ O ~ ~ ~~IL~ ~
F~:~ ~ v I
c) S~ o~ o a~ D O O O
r~
.
a~ ~ ~ O O O O ~ ~ O O O ~ O ~ ~ O
P O-rJ O
V V V V
_ m ~ I ~
~rl ~ O O ~ O ~ ~O O O O
h ~ ~ N
I~ Oooo~ooo~o~1~O~
O
~C a, v v V V v ¢~ _ _ .
~:
~r~ ~ a~ o o o ~co o a~ D
.
I ~C O O O O ~ O O O O ~ O
1~ 0 ~1 ~ a) v v v v ¢ ~
-m E~ I ~;
rl ~ O O C~ O `~ O O OCr~ O
r~
.
I ~C O O O O r~ O O O O O O o Otr) o m o X ~ V V V V V V V
~: ~
~ _ r-J 0~ ~) IS~ C,) OD
~ ~ r~ cO
a~ r! O rl ~0 a~ I O ¢
O ~ ~ ~d r-l r~ m ~ LS~

~ rl ~I O D~
u~ ~j ¢ r~ 1H ~rl 13 ~ ~ ~ O 1~ I
u~ a) li:~ O c)p~ X~Ir~
~rl o ~ r-l ~ ~;C~ ~i 1--1 1 1 1 td ~ H
bO ~ ? C~C) ~ rl ~3 ~rl ~1 ~ ~Id r~ ~1 ~ u~ ~1 O U~ rl ~ O~ : ~
c~
u~ c) c~
~ o O ~ r~
E-l C) c~ C) r-l a o - - o c~
H r-l O ~ rl P~ C) ~r l H H H
.C~ O~rl r l H H r-l ,Da~
Q~ ~ h~) ~rl~rl ~rl~rl O S
t~ 1 V C)C) c) C)c ~ u~ m m m m ~ ~
__ _ . ~

~ ~7581B

L~ L~ Lt~
Lt~Lt~Lt~ Lt~ oLS~ Lr\ ~ o ~ o ~ o o ~ I ~ ~ o ~ ~ ~ o ~ o ~ o Lt~
.
_ ._____ ~OtY~ tY~ tr~ Lt~ tY~ tr) t~ Lt~ ~ t~ ~ t~
LS~~1 ~I N r~l ~ I L~ ~--1 Lt~~--1 L~
...............
tY~ ~D tr~ ~D ~ tY~ t~ ~ tr~

tr)~tr~tY~ t~ tY) ~ DtY~ D tYl Lt~
,1,~ ~ ~ ,~ ~ Lt~ Lt~ L~ ~ Lt~ Lt~ Lf~ ~1 .
trl tr) tr~ ~ ~ ~ ~ ~ ~ t~ ~ ~ ~ tY7 ~D

_ . _ t~ L~ tY t~ tr~ Lt~ ~o tr~ ~ t r-~ ~ ~ ~ ~ ~ Lt~ ~ ~ ~ t,~
.
tY~ ~ ~tr) tr~ ~ t~tY~ trl ~D ~ t~ t~ ~ ~

--l 0r--lH H r-lO H Hr-l rl O O ~I r-l a:) Lt~~o :~
~ Lt~Lt~
t,~ XP:; X t~ ~
IO~ O O O ~ ~ O O
r--l~I ~)r--l rl O O O 1:~ 0 t~) r-l r l ~ ~O
r1 r-lr lr--l ~ ~ 1~ 0 ~ r~l ~ 0 H H
Lr~ o V t~
~ Lt~
N ~t~lt~lt~ 1t,~l t~ 1 Lt~ a) r-lr-lr-l r-lr-l r-l H r~ 0 r l ~1 td I I I I I I I I ~ rl t,d rl O :
r--l rl ~ tl O ~ O _ t C~ t~ ~ O
td ~d ~rl ~rl td H
C) C) r-l t~d ~r-l ~r~ rl ~ t : : ~ rl : r l tl) a~ u, a) ~0 C) C~ rl t/~ u~ r--l 5:~
_ .._. _ _ _ _ _ _ ~ ~7~16 .. ~ . .
U~
IS~ D L~ ~ O LS~ O O O O O ~ L~
I O ~J OO 1~ 0 0 (~
~1 ~1 ~1 ~1 ~1 A A A

I~ D(Y~co ~f) ~15~
~ .~ . . . -~D ~Dr I~f) O O ~J O O OL~\ O ~ (~ ~D
LS~ r I L~ OL~
A

~D L~
u~
~1 ~D~r) ~1 0 0 ~D ~J O(~ L~ \ O ~ ~
O ~I L~ ,-1 t'\l r .
_ ~
r .
D O LD~ J O~1 O O O ~ ~f) ~ 1~

tr~~D01~ 0 L~
O ~`f)r-l O O O ~D ~ D ~D~I O ~I r-l Lr~ t~J r-l V
_ . .

r~l ~I
r-l r-l r-t 0~ O~
r ~ ) (~ O O~
~ W r-~
r-l ~D ~d t~~rl a~ r~ ~D U~
,~ r~~D~ r1 ~) ::t' O
c/~ ~ ~ 0 3 ~r~ D b~
~rl h u~ ~rl ~r/ C~ r~lr-l a) ~ rl F~

X 1 ~
~ P
r-l O r~ ~ ~ ~O
4~ u~~da l~ ~ a) E3 u~ ~rl rla~
~Ir l~::> h h C~ O ~
~ rlr l t~ L~ O
rl a) (I) ,e O : -~rl~rlr~lr-l O O O~ O O(I) ~ h u~

.

~ 175~16 Lr~
L~L~oooooL~o r~ o o o o ~ o ,, A ~ A A

~ Lr~ Lf~ ~
Lr~ ~ ~ ~ ~
L~ Lr~ Lr~O ~
J O O
A A

Lf~ ~D ~ L~ ~
L~ L~ Lr~ L~
~D ~ rr~ ~D ~ ~ ~ O ~ O
~1 ~1~I L~ O

Ln ~ ~ L~
.
L~ Lf~ L~ O ~ O
r~ J L~\ O
A
_ rr) ~ ~O
L~ Ln ~ ~ Lr~Lr~ L~ L~
~J H ~1 tr'~ J N O ~ O
~ L~ ~
.
~0 ~
r~ L~ L~ ~ O
rn cr~
~1 r l H ~Z;o~ I H r1~ I r~
v o~ m ~
rl rl~ rn ~
O O ~rl S
bO ~ o Q~
a~

ra ,1rn rn ~ P ~ ~
o _ _ : - :- e ~ o o a) u~
ra orn rn _ . ~ ~

~ ~7~81B

~ 'rom Tables 1 and 2, it is seen that the new com-pounds of this invention according to the formula (I), including the compounds of the formulae (II), (III), (IV) and (V), effectively inhibit the growth of many kinds of bacterial strains. The new compounds of this invention show a low acute toxicity to animals, including men. It has been found that the new compounds of the formulae (II) and (III) according to this invention, such as l-N-[(S)-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxy-kanamycin B; l-N-[3-amino-2-hydroxypropionyl]-5,3',4 r _ trideoxykanamycin B; l-N-~(S)-4-amino-2-hydroxybutyryl]-5,3',4',6l'-tetradeoxykanamycin B; and 5,3',4',6"-tetra-deoxykanamycin B exhibit an LD50 value of 25 to 50 mg/kg when their acute toxicity is estimated by intravenous injection in mice. It has also been found that the new compounds of the formulae (III) and (IV) according to this invention, such as l-N-~(S)-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxy-6'-N-methylkanamycin B; 1-N-(3-amino-2-hydroxypropionyl)-5,3',4'-trideoxy-6'-N-methylkanamycin B, 1-N-[(S)-5-amino-2-hydroxyvaleryl]-5,3',4'-trideoxy-6'-N-methylkanamycin B and 5,3',4'-trideoxy-6'-N-methyl-kanamycin B exhibit an LD50 value of 50 to 100 mg/kg when their acute toxiclty is estimated by intravenous inJection in mice.
The new compounds of this lnvention are usually obtained in the form of its free base or a hydrate or a ~ ~7~6 carbonate thereof. The new compounds of this invention each may readily be converted into a form of a pharma-ceutically acceptable acid addition salt thereof~ such as the hydrochloride, hydrobromide, sulfate, phosphate, nitrate, acetate, maleate, citrate~ ascorbate, methane-sulfonate and the like by reacting with the appropriate, pharmaceutically acceptable inorganic or organic acid in an aqueous medium.
The new compounds of the formula (I), tII), (III), (IV) or (V) according to this invention and its pharma~
ceutically acceptable acid addition salt may be administered orally, intraperitoneally, intravenously, subcutaneously or intramuscularly using any pharmaceutical form known to the art for such administration and in a similar manner to the known kanamycins. For instance, the new compounds of this invention may be administered orally using any pharmaceu-tical form known to the art for oral administration.
Examples of the pharmaceutical forms for oral administration are powders, capsules, tablets, syrup and the like. A
suitable dose of the new compounds of this invention for e~fective treatment of bacterial infections is in a range of 0.1 to l g. per person a day when it is given orally.
It is preferred that said dose should be orally administered in three to four aliquots per day. The new compounds of this invention may also be admlnistered by intramuscular inJection at a dosage of 50 to 500 mg per person two to ~ .~758~6 four times per day. Moreoverg the new compounds of this invention may be formulated into an ointment for external application which contains the active compound at a con-centration of 0.5-5% by weight in mixture with a known ointment base such as polyethylene glycol. Furthermore, the new compounds of this invention are each useful for sterilization of surgieal instruments and sanitary materials.
Aecording to a second aspeet of this invention, therefore, there is provided an antibacterial composition comprising as the active ingredient a l-N-[a-hydroxy~
aminoalkanoyl]-5,3',4'-trideoxykanamycin B, a l-N-[~-hydroxy-~-aminoalkalloyl]-5,3',4',6"-tetradeoxykanamycin B
or a pharmaceutically aceeptable aeid-addition salt thereof as defined by the formula (II) or 5~3',4',6"-tetradeoxy-kanamyein B or a pharmaeeutieally aeceptable aeid-addition salt thereof as defined by the formula (III) in an antibacterially effeetive amount to inhibit the growth of baeteria, in eombination with a earrier for the ac~ive in~redient compound, as well as an antibacterial composi-tion eomprising as the aetive ingredient a l-N-[~-hydroxy-~-aminoalkanoyl~-5,3',l~'-trideoxy-6'-N-methylkanamyein B
or a pharmaeeutieally aeeeptable aeid additlon salt thereof as defined by the formula (IV) or 5,3',l~'-trideoxy 6'-N
methylkanamycin B or a pharmaceutieally acceptable aeid-addition salt thereof as defined by the formula (V), in I ~75816 an antibacterially effective amount to inhibit the growth of bacteria, in combination with a carrier for the active ingredient compound.
Next, the production of the new compound of the formula tII), according to this invention is described.
Thus, the new compound of the formula (II) such as l-N-[(S)-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxy-kanamycin B and l-N-[(S)-4-amino-2-hydroxybutyryl]-5,3',4',6"-tetradeoxykanamycin B can be synthetized by using as the starting compound either the known substance 5,3',4'-trideoxykanamycin B (Japanese Journal of Anti-biotics, 32, S-178 (1979)) or the new compound 5,3',4'~6"-tetradeoxykanamycin B as obtained according to this invention and condensing the l-amino group of the starting compound with a corresponding ~-hydroxy-~-amino alkanoic acid or a functional equivalent thereof.
According to the third aspect of this invention, therefore, there is provided a process for the production of a 1-N-[~-hydroxy-~-aminoalkanoyl]-5,3',4'-trideoxy~
kanamycin B or l-N-[~-hydroxy-~-aminoalkanoyl]-5,3',4',6'7-tetradeoxykanamycin B represented by the formula (II) ~ ~7~6 R
HO ~ O \ H2N

H2N \ ~ ~NH2 (II) HN ~ NH2 CO

CHOH
(CH2)nNH2 wherein R is a hydroxyl group or a hydrogen atom and _ is an integer of 1, 2 or 3~ which comprises:-(a) acylating the l-amino group of 5,3',4'-tri-deoxykanamycin B or 5,3',4',6'r-tetradeoxykanamycin B
represented by the formula (VI) 6"

HO \ H2N ~

H2N ~ OU ~ ~ ~ (VI) O ~ NH2 H2N~/--\\,~ NH2 whereln R is as de~ined above, or a partially amino-protected derivative of 5,3',4'-trideoxykanamyci.n B or 5,3',4~,6"-tetradeoxykanamycin B represented by the ~ormula (VI') ..

~ ~7~6 ; ~
H2N 1 ~ B

wherein R is a hydroxyl group or a hydrogen atom~ and A
is a hydrogen atom and at least one B is a mono-valent amino-protecting group but the other B(s) is or are each a hydrogen atom, or at least one pair of A and B taken together form a di.-valent amino-protecting group but the other A and B are each a hydrogen atom, and the amino-protecting groups represented by A and B may be equal to each other or dif~erent from each other, by reaction with an a-hydroxy-~-aminoalkanoic acid or an amino-protected derivative thereof represented by the formula (VII3 A~
B~ > N(CH2)nlCHCH (VII) ~ H
wherein A' is a hydrogen atom and B' is a hydrogen atom or a mono-valent am~no-protecting group, or A' and B' taken together form a di-valent amino protecting group and n ls an integer of 1, 2 or 3, or a functional equivalent of the compound (VII), to produce the l-N-acylated product represented by the formula (II') 31 ~75~16 6"

~1 ~ NH2 ~NH2 (II') CO
CHOH
(CH2)nN - B~

or by the formula (II") R ~ A
HO ~ ~ \ B ~N ~

A ~ M \ ~ ~ ~ ~ N

N A (II") CO
CHOH
( CH2 ) nN ~
~ B' wherein R, A, B, A', B' and n are as def'ined above, and (b) removing the remaining amino-protecting group(s) where existts), f'rom the l-N-acylated product of' the f'ormula (II') or (II") in a known manner to produce the compound of' the f'ormula (II).

, ' : .

.

1 ~7~16 The process oF the third aspect of this invention may include a further step of converting the compound (II) into a pharmaceutically acceptable acid-addition salt thereof by reacting with a pharmaceutically acceptable inorganic or organic acid in a known manner, if desired.
The procedures ~or carrying out the process of the third aspect of this invention are now described in more detail.
In carrying out the present process, it is possible to employ as the starting compound 5,3',41-trideoxy-kanamycin B or 5~3',4',6T'-tetradeoxykanamycin B (VI) of which amino groups are not protected at all, in the rorm of the free base or in the form of an acid-addition salt with an appropriate acid such as hydrochloric acid or sul~uric acid. However, it is preferable to employ as the starting compound such a partially amino~protected derivative of 5,3',4'-trideoxykanamycin B or 5,3',4',6"-tetradeoxykanamycin B according to the formula (VI') in which all or some of the amino groups other than the l-amino group have been protected with known amino-protecting group(s) and which may be prepared by lntroduetion of a known amino-protecting group into the eompound of the formula (VI) by means of a known amino-proteeting teehnique previously adopted in the synthesis of some known deoxy derivatives of kanamycin B. For the preparation o~ the partially amino-protected 5,3',4'-~.~7~6 - 31 ~

trideoxykanamycin B or 5,3',4',6"-tetradeoxykanamycin B
of the formula (VI'), it is feasible to utilize the amino-protecting techniques which were employed, for instance, in the preparation of the 6'-N-benzyloxycarbonyl derivative of kanamycin B as described in the specification of U.S. patent No. 3,781,268 or U.S. patent No. 3,929,762;
the preparation of 2',6'-di-N~tert-butoxycarbonyl-kanamycin B or 6'-N-benzyloxycarbonyl-kanamycin B, or the mono-N- or di-N-tert-butoxycarbonyl and even tri-N-tert-butoxycarbonyl derivative of 6'-N-benzyloxycarbonyl-kanamycin ~, ei.ther isolated or in mixture thereof~ as described in the specification of U.~. patent No. 1,426,908 or U.S. patent No. 3,939,143; or the preparation of 2',3,3",6'-tetra-N-formyl derivative of kanamycin B as described in the specification of Belgian patent No. 817,546.
In general, suitable examples of the amino-protecting group which may be used for the protection of some amino groups in the partially amino-protected derivative of the formula (VI') may be an ordinary amino-protecting group, including an alkoxycarbonyl group such as tert-butoxy-earbonyl and tert-amyloxycarbonyl; a cycloalkyloxyearbonyl group sueh as eyelohexyloxyearbonyl; an aralkyloxyearbonyl group such as benæyloxycarbonyl; an acyl group such as trifluoroacetyl and o-nltrophenoxyacetyl; a phosphinothioyl group such as diphenylphosphinothioyl and dimethylphos-phinothioyl; a phosphinyl group such as diphenylphosphinyl, ~ ~5~6 and the like. Preferred examples of the di-valent amino-protecting group include phthaloyl group and a group of Schiff base type such as salicylidene. The introduction of the amino-protecting group of these kinds may be conducted by reacting the compound of the formula (VI) with an appropriate known reagent for introduction of the amino-protecting group which may be in the form of an acid halide, acid azide, active ester or acid anhydride and the like, in the manner known in the conventional synthesis of peptides. By chosing the quantity of the reagent for introduction of the amino-protecting group employed in a proportion of 0.5 to 6 mol. per mol. of the compound of the formula (VI), it is possible to prepare a mixture of different 3 partially amino-protected derivatives (VI') at any ratio, due to the difference in the reactivity of the respective amino groups of the compound (VI).
In the process of the third aspect of this inven-tion, it is practical to employ as the starting compound such amino-protected 5~3'~4l-trideoxykanamycin B or 5,3',4',6"-tetradeo~ykanamycin B derivative in which all or some of the amino groups other than the l-amino group have or has been blocked, for example, a 3,2',6',3"-tetra~N-protected derivative, a 3,2',6'-tri-N-protected derivative, a 2',6',3"-tri-N-protected derivative, a

2'~6'-di-N-protected derivative and a 6'-mono-N-protected ~ ~75~1 derivative. Besides, a mixture of two or more of these partially N-protected derivatives may, without being purified, be used for the l-N-acylation step of the present process.
In order to ensure that the desired product of the general formula (II) can be produced in a high yield in accordance with the process of the third aspect invention, it needs only that just the l-amino group of the compound of the formula (VI)g namely 5,3',4'-trideoxykanamycin B
or 5,3',4~,6'r-tetradeoxykanamycin B is selectively acylated with the a-hydroxy-~-aminoalkanoic acid (VII). Accordingly, : it will be evident that most preferably 9 a 3,2',6',3"-tetra-N-protected derivat~ve of the compound (VI), that is, the amino-protected derivative of the compound (VI') in which all the amino groups other than the l-amino group have been blocked with the protectlve groups is employed as the starting compound to be l-N-acylated in the present process.
To prepare the 3,2',6',3"-tetra-N-protected deriva-tive of the formula (VI') from the compound of the formula (VI), the ~ollowing procedure may be used, for instance.
Thus, there can be applied a known method of U.S. patent No. 4,136,254 o~ Nagabhushan et al by which a 3,2',6'-tri-N-acylated protected derivative o~ kanamycin B is prepared by reacting kanamycin B with a di-valent transition metal cation, for example, cation of copper (II), nickel (II), ~ . , .

~ 1l75~16 cobalt (II), etc. for the formation of a metal complex of kanamycin B, reacting this kanamycin B-metal complex with an acylation agent known as the amino~protecting group introducing reagent for the protection of all the amino groups other than the l-amino and 3"-amino groups of the kanamycin B moiety of the kanamycin B-metal complex ~said 1- and 3"-amino groups having been blocked by complexing with the di--valent metal cation in the kanamycin B-metal complex), and ~hen removing the di-valent me~al cation from said complex, eg. by treatment with hydrogen sulfide or by trea~ment with aqueous ammonia. Or, there can be applied ; - the method of published U.K. patent application 2,036,020 A
or Belgian pa-~ent~No. 879,925, by which a 3,2',6'-tri-N-acylated protected derivative of kanamycin B is prepared in a similar way to.the aforesaid known method of Nagabhushan et al except that zi~nc cation is employed instead of the d;-valent transition metal cation. In thi~s way, a 3~2',6'-. tri-N-protected derivative of the formula (VI'). can be prepared from the compound of the formula ~VI). in a hi.gh yiel~. The 3"-amino grou~ of this 3,2',6'~.tri~N-protected der.Lvative (VII~ so prepared can further be protected by the selective acylation according to a selective. 3"-N-`
acylation method (.see claim 15 of Belgian patent No~ 879,~23 i - 34 -b.' mab/~

:: , ~ ~58~6 for the production of an amino-protected derivative of an aminoglycosidi.c antibiotic of which all tKe amino groups other than the l-amino group have been protected selectively, so that a 3,2',6',3"-tetra-N-protected derivative of the compound (VI) can be prepared in a high yield. In accor~
dance with the selective 3"-~-acylation method as described in claim lS of Belgian patent No. 879,923, the above-mentioned 3j2',6'-tri-N-protected derivative o~ the compound : (VI) is reacted with.a formic acid alkyl ester, a di-halo or tri-halo-alkanoic acid alkyl ester, formylimidazole or an N--alkanoyl-imidazole as the acylation agent, whereby the

3"-amino group can be acylated selectively with the acyl residue o~ the acylat;on agent employed in a high yield, wi~th.out involving the acylatïon of the l~amino group of said 3,2l,6'~-tri-N-protected derivatiYe. The 3,2',2~,3"-tetra~
N-acylated derivatlve, for example, 3,2.',6'-tri~N-benzyloxy-carbonyl-3"-N-trifluoroacetyl derivative, of 5,3',4'-tri-deoxykanamycin B or 5,3',4',6"-tetradeoxykanamycin B which may be obtained by applying the above-~mentioned methods of 20. the U,S. patent No. 4,1`36,254 and of the Bel~ian patent No.
8~,923 is a most preferred starting compound to be l-N-acylated selectiyely with the a-hydroxy-w-aminoa1kanoi~c acid (~yII) in the l-N-acylation step of the - ~ ~ - 35 -mab~7 `

1~7 present process.
In the process of this third aspect invention, the l-amino group of the compound of the formula (VI) or the l-amino group of the partially amino-protected derivatives (VI') thereof, either ~solaked or in mixture of two or more of them, is acylated with the ~-hydroxy-~-aminoalkanoic acid of the formula (VII) A' B~ / N (C~2)n IHCOOH (VII) OH

wherein A' and B' are as defined above and _ is an integer of 1, 2 or 3 of which the amino group is not protected or has been protected. This ~-hydroxy-~-aminoalkanoiç acid may be 3-amino-2-hydroxypropionic acid (ie. the compound of the formula (VII) where _ is 1 and A7 and B' are the hydrogen atoms), I~-amino-2-hydroxybutyric acid (ie. the compound of the formula (VII) where n is 2 and A' and B' are the hydrogen atoms) or 5~amino-2-hydroxyvaleric acid (ie. the compound of the formula (VII) where is 3 and A' and B' are the hydrogen atoms). Amongst them, the (S)-isomer is preferred for use.
In the process of the third aspect invention, the l-N-acylation with the ~-hydroxy-~-aminoalkanoic acid (VII) may be conducted according to any of one conventional methods for the synthesis of peptides, for instance, according to the known dicyclohexylcarbodiimide method, I ~ 7 the known mixed acid anhydride method, the known azide method or the active ester method and the like, using the ~-hydroxy-~-aminoalkanoic acid as such or in the form of its reactive derivative (as the ~unctional equivalent thereof). For the amino-protecting group for protection of the amino group of the a-hydroxy ~-aminoalkanoic acid may be employed such an amino-protecting group which is the same as or different ~rom the one present in the starting compound (~I'). Particularly, a preferred amino-protecting group ~or this purpose is tert-butoxycarbonyl group which is easily removable by treatment with aqueous trif'luoroacetic acid or acetic acid or with diluted aqueous hydrochloric acid. Benzyloxycarbonyl group which is removable by a conventional hydrogenolysis in the presence of a catalyst such as palladium or platinum oxide is a convenient N-protecting group.
The l-N-acylation in the present process may pre-ferably be carried out in an aqueous organic solvent according to the active ester method using and ~-hydroxy-~-aminoalkanoic acid in the form o~ its active ester. For example, N-hydroxysuccinimide ester of L 4-benzyloxy~
carbonylamino-2-hydroxybutyric acid may preferably be used as the active ester which may be prepared by a conventional method of prepari.ng the active ester. This active ester preferably may be used in a proportion of frorn 0.5 to 3 molar equivalents and preferably of from 1 to 1.5 molar . , ~ .

~ .
, ~75~16 equivalents per mol of the starting compound (VI) or (VI') to be l-N-acylated. The aqueous organic solvent used in the reaction mediurn may be a water-miscible organic solvent such as dioxane, 1,2-dimethoxyethane, dimekhylformamide, tetrahydrofuran, and the like. The l-N-acylation may be effected at ambient temperature or, if desired, at an elevated temperature of 20-90C and for a reaction time of several hours and preferably of 5-6 hours.
When the l~N-acylation in the present process is conducted using as the starting compound such as a partially amino-protected derivative in which some, but not all, of the amino groups other than the l-amino group has or have been protected, for example, the 6'-N-protected derivative of the starting compound (~I), the acylation products as formed may partially be purified by a column chromatography, for example, on silica gel so that the unreacted starting material is removed, giving a mixture of the desired ; l-N-mono-acylated product with the otherwise N-acylated products, as the case be in the synthesis of habekacin, namely 1-N-[(S)-4-amino-2-hydroxybutyryl]-3',4'-dideoxy-kanamycin B as described in the specification o~ U.S.
patent No. 4,107,424. These mixed acylation products may~ without being puri~ied and/or isolated, be subjected immediately to the subsequent de-protecting step of the 2~ present process, followed by the purification and isolation so that the desired l-N-mono-acylated product is obtained.

.

, ~ ' ' -~ ~758 In the second step of the process of this third aspect invention, the l-N~acylation product (including the mixed acylation products) as obtained in the l-N-acylation step of the present process is subjected to the removal of the amino~protecting groups, if these are still remaining in the l-N-acylation product. The removal of the protecting groups is effected by a conventional deprotecting technique. Thus~ the amino-protecting group of the alkoxycarbonyl type is removed by weak acid hydrolysis with an aqueous solution of trifluoroacetic acid or acetic acid and the like or with a diluted aqueous solution of an inorganic acid such as hydrochloric acid.
The aralkyloxycarbonyl group such as benzyloxycarbonyl may be removed by an ordinary catalytic reduction (hydro-genolysis~-. When-phthaloyl group is present as the amino-protecting group, it can be removed by heating in a solution of hydra~ine hydrate in a lower alkanol.
The deprotected acylation product as obtained from the second, de-protecting step of the present process may contain the desired l-N-acylation product of the formula (II) together wi~h some isomers thereo~. The desired l-N-(a-hydroxy-~-aminoalkanoyl) derivative (II) may be isolated and puri~ied chromatographically using a cation-exchanger containing carboxylic ~unctions, such as Amberlite CG-50 ta product of ~ohm & Haas Co., U.S.A.) or CM-Sephadex C-25 (a product o~ Pharmacia Co., Sweden) and assaying the ; ,, *trade mark ~ ~758~

antibacterial activity of the fractions of the eluate by means of a proper ~anamycin-sensitive strain and kanamycin-resistant s~rain of bacteria.
The 5,3',4',6"-tetradeoxykanamycin B which is used as the starting compound in the process for the pro-duction of a l-N-(~-hydroxy-~-aminoalkanoyl)-5,3',4',6"~
tetradeoxykanamycin B in accordance with the third aspect of this invention may be prepared starting from 3',4',6"-trideoxykanamycin B already synthesized by the present in~entor ~this compound was referred to as 6"-deoxydibekacin în.the specification of published U.K. patent application 2,058~774 A) or an N,O-protected derivative thereof repre-sented by the formula (VIII-'). .
.
DO ~ o \ B -~N ~

B,,N ~ ~ 1~ (VIII') B ~ N N `~B

.

wherein A is a hydrogen atom and B is a mono-valent amino-protecting group, or A and B taken together form a di-valent amino-protecting group, and D is a hydroxyl-protecting acyl group.

According to the fourth aspect of this invention, therefore, there is provided a process for the producti.on mab/

- 41 ~7~816 of 5,3',4'~6"-tetradeoxykanamycin B as described herein-before and represented by the formula (III) HO ~ \ H2N

H N \ ~ ~
2 OH ~ " ~-o NH2 (III) 0~ \
~NH2 H2N~
which comprises the steps of:-5` (a) protecting the 4"-hydroxyl group of a penta-N-protected and 2"-0-protected derivative of 3',4',6"-krideoxykanamycin B represented by the formula (~III) OH ~ ~ (VIII) 0~0 N~BA

B ~ N i \ N ~-A

wherein A is a hydrogen atom and B is a mono-valent amino-protecting group, or A and B taken together form a di-valent amino-proteating group, and D is a hydroxyl-protecting acyl group, with a mono-valent hydroxyl-protecting acyl g:roup of the same klnd as the hydroxyl-protecting group (D) present in the 2"-position of the compound (VIII) to produce the

4"-O-protected compound of the formula (VIII') ' ` ' "
:
. ~

~ ~7~816 t~ N ~ (VIII') BA ~ N N B

wherein A, B and D are as defined above, (b) reacting the 41'-O-protected compound of the formula (VIII') with sulfuryl chloride to replace the

5-hydroxyl group thereof with a chlorine atom to produce the corresponding 5-chloro derivative, (c) reducing the 5-chloro deriv,ative to remove the 5-chloro group to produce a protected derivative of 5,3',4',6"-tetradeoxykanamycin B represented by the formula (IX) DO ~ \ B ,, N

~N ~ \B (IX) ~ ~0 A " N ~ N B

wherein A, B and D are as deflned above, and (d) removing the remaining hydroxyl-protectlng groups and the remaining amino-protecting groups in a known manner from the compound of the formula (IX) to produce the compound of the formula (III).
In the process of the fourth aspect invention, the amino-protecting groups present in the penta-N-protected and 2"-O-protected 3',4'36"-trideoxykanamycin B of the formula (VIII) employed as the starting material may be of the same kind as those present in the starting compound of the formula (VI') which is employed in the process of the third aspect invention as described hereinbefore. The preparation of the starting compound of the formula (VIII) is described hereinafter.
In the first step of the process according to the fourth aspect invention, the 4"-hydroxyl group of the starting compound (VIII) is protected with a mono-valent hydroxyl-protecting group of acyl type which may be a lower alkanoyl group such as acetyl or an aroyl group such as benzoyl. Introduction of such hydroxyl-protecting acyl group into the 4"-hydroxyl group of the starting compound (VIII) is achieved readily by reacting the starting com-pound (VIII) with an appropriate acylation reagent in theform of acid anhydride, acid halide or active ester in a known manner, f`or example, in an organic solvent such as pyridlne at a temperature of 10-50C, pre~erably at ambient temperature. Preferred acylation reagent for this purpose is acetyl chloride or benzoyl chloride. In this acylation reaction, the 5-hydroxyl group of the starting ~ 17581 -- 44 ~

compound (VIII) is hardly acylated by the acylation reagent owing to the lower reactivity of the 5-hydroxyl group.
In this wayl there is produced the 1,3,2'6',3"-penta-N-protec~ed and 2" 9 4"~di-0-protected derivative of 3. ~t ,6"-trideoxykanamycin B of the formula (VIII').
In the second step of the present process, the protected derivative (VIIII) so obtained is sub~ected to the deoxygenation at the 5-hydroxyl group thereof in a known manner as described in the Bulletin of the Chemical Society of Japan, Vol. 51, page 2354 (1978). Thus~ the protected derivative (VIII') is reacted with a 1 to 5 -~ . molar proportion of sulfuryl chloride in an organic solvent such as dry pyridine at a temperature lower than ambient temperature ror 2 to 20 hours under agitation, af.fording the 5-chloro derivative.
In the third step of the present process, the 5-chloro derivative so obtained is redueed to effect the dehalogenation. This removal of the 5-chloro group may be achieved by reaction with a metal hydride such as tributyl tin hydride as described in the above-mentioned document or by conventional catalytic hydrogenation in the presence o~ Xaney nickel. In this way, there is produced the N~0-protected derivative o~ 5,3',4',6"-tetradeoxykanamycin B o~ the formula (IX).
In the fourth step of the present process, the N~0-protected 5,3l,4',6"-tetradeoxykanamycin B derivative *trade mark :

I ~7~

(IX) is subJected to the deprotection. The mono-valent hydroxyl-protecting acyl groups (D) present in the 5-deoxygenated compound (IX) can easily be removed by alkaline hydrolysis at ambient temperature, for example, by dissolving the compound (IX) into ammoniac methanol (ie. a mixture of aqueous ammonia and methanol). The amino-protecting group present in the starting compound (VIII) is of the aralkyloxycarbonyl type~ the amino-protecting group of this nature can be removed concur-rently to the catalytic hydrogenation to which the 5-chloro deri~vative is subjected in the third step of the present proce~s. The amino-protecting groups other than the aralkyloxycarbonyl group can readily be removed in a known manner, for example, by hydrolysis wlth weak acid. When the amino-protecting group is a lower alkoxycarbonyl group such as ethoxycarbonyl, it can be removed by alkaline hydrolysls with barium hydroxide.
In the process of the fourth aspect invention, it is possible to carry out such a modified process in which 3',4',6"-trideoxykanamycin B is used as the intiial material, its five amino groups are protected and sub-sequently its two 2"- and li"-hydroxyl groups are protected at once with the same mono-valent hydroxyl-protecting groups (D) to prepare the N,0-protected derivative of the formula (VIII').
The preparation of the penta-N-protected and ', ~ : :

~ J17~816 2"-O-protected derivative of 3',4',6"-trideoxykanamycin B
of ~he formu].a (VIII~ employed as the starting compound in the process of the fourth aspect invention may be conducted -as described in the specification of published U.K. patent application 2,058,774. Thus, a penta-N-protected derivative of 3',4'-dideoxykanamycin B represented by the formula B (1) ` ~ B - N l 3 N ~ B
wherein A and B are as defined hereinbefore in respect of the formula (VIII) is used as the initial material, the : lO two 4"- and 6" hydroxyl groups thereof are protected s1multaneous1y with a di-valent hydroxyl-protecting group such as isopropylidene group, the 2"-hydroxyl group thereof is protected with a mono-valent hydroxyl-protectlng acyl : group such as benzoyl and acetyl to produce a 2",4",6"-lS trl-0-protected derivative of the formula

6"

\ C ~ 0D ~ ~ A
: B ~ 0 ~ ~B

. ~ N ~ N B
.~
-.

~' wherein A and B are as deflned above, the group \ C /
y /
is a di-valent hydroxyl-protecting group where X and Y are each a hydrogen atom, an alkyl group of 1 to 4 carbon, an aryl group such as phenyl or an alkoxyl group of 1 to 4 carbon atoms, or the group X
: \ /
~ ~ y/ \
denotes a cyclohexylidene group or a tetrahydropyranylidene group, and 3 is a mono-valent hydroxyl-protecting acyl group. The 2",4",6"-tri-0-protected derivative of the formula (2) so obtained is treated with aqueous acetic acid to remove the group (y ~ C =) of protecting the 4"-and 6"-hydroxyl groups the~refrom, and the product so partially deprotected is reacted with an appropriate sulfonylation reagent such as p-toluenesulfonyl chloride in pyridine to preferentially sulfonylate the 6"-hyclroxyl group thereof and to produce a 6"-0-sulfonylated derivative of the formula : ~ . , : . ~ , . - ,, -:
, . - . . , - .

, ~ 8 GS0 ~ A
H0 ~ \ B N ~

A \ ~ O ~ ` ~ / ~ N A

A = N N B

wherein A, B and D are as defined above and ~ is a lower alkyl group, especially an alkyl group of l to 4 carbon atoms, an aryl group such as phenyl or p-methylphenyl or . an aralkyl group such as benzyl. The 6"-O-sulfonylated derivative obtained is then treated with an alkali metal iodide or bromide to replace the 6"-sulfonyloxy group (GSO3-) by the iodo or bromo group and thereby to produce a corresponding 6"-iodo or 6"-bromo derivative (correspond ing to such a compound of the formula (3) but where the group GSO3- has converted into the iodine or chlorine atom), which is subsequently reduced with hydrogen in the presence of a known hydrogenation catalyst such as palladium to effect the dehalogenation, giving the penta-N-protected and 2"-O-protected 3',4',6"-trideoxykanamycin B derivative of the f`ormula (VIII) as desired.
~urther7 the production of the new compound of the ~ormula (IV) accord~ng to this invention is described here.
Thus~ the new compound o~ the formula (IV) such as l-N-[(S)-4~amino-2-hydroxybutyryl~-5,3',4 ~ -trideoxy-6'-N-I 1i 7 ~

methylkanamycin B, l-N-(3-amino-2-hydroxypropionyl)-5,3',4'-trideoxy-6'-N-methylkanamycin B and l-N-[(S)-5-amino-2-hydroxyvaleryl]-5,3',4'-trideoxy-6'-N-methyl-kanamycin B can be synthetized by using as the starting compound the new compound 5,3',4'-trideoxy-6'-N-methyl-kanamycin B as obtained in accordance with this invention and condensing the 1-amino group of this starting compound with a corresponding a-hydroxy-~-aminoalkanoic acid or a functional equivalent thereof.
According to the fifth aspect of this invention, therefore, there is provided a process for the production of a l-N-[~-hydroxy-~-aminoalkanoyl]-5,3', L~ ~ ~trideoxy-6'-N-methylkanamycin B as described hereinbefore and repre-sented by the formula (IV) HO
HO ~ O\ H2N ~

H2N ~ ~ ~ ~ NHCH3 ~
HN ~ NH2 (IV) CO
I

CEIOH
(C~I2)nNH2 wherein n is an integer of 1, 2 or 3, which comprises:-I f~7~16 (a) acylating the l-amino group of 5,3',4'-trideoxy-: 6'-N-methylkanamycin B represented by the formula (V) HO
HO ~ O\ H2N ~

~' ~ H2~ ~ ~ ~ (V) :' : :OH I ¦ NHCH
~ o 3 o ~` H~2l ~ ~ ~ ~ IB2 or a partially amino-protected derivative of 5,3':,4:'~
trideoxy-6'-N-methy~lkanamycin B represented by the~formula A ~ ~ ;~ ; B
B OH~ : N-~3( ) whereln A is:~;a hydrogen~at~om~and'at~least one~ B is a~
mono-valent~amino~-p:rote~ct~ing group but th~e other B(s)~
1;0: ~ is or:are ea;ch a~h~drogen atom,~or~at:least one pair of ;
A and B taken together~form a:di-valent~amln'o-protect;ing group but the other A and B~are eaoh a hydrogen at~om, and : ~ the amino-protectlng~groups~represented by A and B may be equal to each other or dlf~erent ~rom each other, by~
reaction with an a-.hydroxy-~-aminoal~anoic acld:or an : amlno-proteoted derlvative thereo~ represented by the ~ :

, ~ :

~. . .

, ~- - . . ~

~ 775~.~6 formula (VII) A' / N(CH2)nfHCOOH (VII) B' OK
wherein A' is a hydrogen atom and B' is a hydrogen atom or a mono-valent amino-protecting group, or A' and B' taken together form a di-valent amino-protecting group and _ is an integer of 1, 2 or 3, or a functional equivalent of the compound (VII), to produce the l-N-acylated product represented by the formula (IV') H~ / ~ o ~ ~ N /

NH2 (IV') HN

CO
CHOH
(CH2)nN ~ B~

or by the formula (IV") 1 1~5~16 HO B /

N ~ OH ~ ~ N

A
7N - B (IV") CO

CHOH
I,, A
(CH2)nN B~
wherein A~ B, A', B' and n are as defined above3 ancl (b) removing the remaining amino-protecting group~s) where exist(s~ ~rom the l-N-acylated product of the formula (IV') or (IV") in a known manner to produce the compound of the formula (IV).
The process of the fifth aspect of this invention may include a further step of converting the compound ~VI) as produced into a pharmaceutically acceptable acid-addition salt thereof by reacting with a pharmaceutically acceptable inorganic or organic acid in a known manner, if desired.
The process of the fifth aspect invention can be ; carried out in the same manner as described hereinbefore for the process o~ the third aspect of this invention.
In carrying out the process of the ~ifth aspect invention, it is feasible to employ as the starting com-pound 5,3',4'-trideoxy-6'-N-methylkanamycln B of the formula ~ `,,' ~ . ~
, - ,, ~ 1~58~6 (V) of which amino groups are not protected at all, in the form of the free base or in the form of an acid-addition salt with an appropriate acid such as hydrochloric acid.
However, it is preferred to employ as the starting compound such a partially amino-protected derivative of 5~3',4'-trideoxy-6'-N-methylkanamycin B according to the formula (V') in which all or some of the three amino groups and methylamino group other than the l-amino group have been protected with known amino-protecting groups and which may be prepared by introduction of a known amino-protecting group into the compound (V) as described detailedly in respect to the process of the third aspect invention.
In the process of the fifth aspect invention, the step of 1-N-acylating the starting compound (IV) or (IV') ; 15 and the step of deprotecting the l-N-acylated product (IV') or (IV") as well as the step of purifying the deprotected l-N~acylation product are worked out just as described hereinbefore in respect of the corresponding steps of the process of the third aspect invention.
The new compound of the formula (V), namely 5,3',4'-tri-deoxy-6'-N-methylkanamycin B which is used as the starting compound i.n the process of the aforesaid fifth aspect invention may be prepared starting from a known compound, 5,3',4'-trideoxykanamycin B (Japanese Journal of Antibiotics, Vol. 32, S-178 (1979)) and conducting N-methyl-ation at the 6'-amino group of said starting compound in . ~, .
.

~7~6 the same manner as described in U.S. patent No. 3,925,353 or the "Journal of ~ntibiotics" 25, 743 (1972).

According to the sixth aspect of this invention, 5 there is provided a process for the production of 5,3',4'-trideoxy-6'-N-methylkanamycin B represented by the formula (V?
HO

HO ~ \ H2N

- H2N ~/~ ~ \~`
: : . OH I ¦ (V) ! ~o NHCH3 H2N ~NH2 ., which comprises the steps of:-(a) introducing an alkyloxycarbonyl group, a cycloalkyloxycarbonyl group or an aralkyloxycarbonyl group into the 6'-amino group of 5,3',4'-trideoxykanamycin B
: represented bg the formula ~X) HO
~/ ~ H2N ~

H2N~ \~ (X) Io~

H2N ~ MH2 .

~ ~7~

to produce the compound of the formula (XI) HO
HO ~ O H2 H2N~ r ( XI) OH \ ~ O NH8R3 H2N~H2 wherein R3 is an alkyl group of 1 to 6 carbon atoms, a cycloalkyl group of 3 to 6 car~on atoms or an aralkyl group, particularly a phenyl-(Cl-C4)alkyl group, especially benzyl, and (b) reducing the compound of the formula (XI) with a metal hydride in an anhydrous organic solvent to produce the compound of the formula (V) The procedures for carrying ouk the process of the sixth aspect invention are now described.
In the first step of the present process, an alkyloxycarbonyl group, a cycloalkyloxycarbonyl group or aralkyloxycarbonyl group is introduced into the 6'-amino group of the starting compound (X) and may be the one which is usually known as the amino-protecting group of urethane type. Introduction of the alkyloxycarbonyl, cycloalkyloxycarbonyl or aralkyloxycarbonyl group (-COR3) into the 6'-amino group of the starting 5,3',4'-trideoxy-kanamycin ~ (X) is achieved in the same manner as described ' , ~ ~7581B

hereinbefore for the preparation of the amino-protected derivative of the starting material (VI') which is employed in the process of the third aspect invention. The selective protection of the 6'-amino group can be made because the 6'-amino group is most reactive amongst the amino groups of the kanamycin B compound (X). The group (-C0~3) to be ., O
intorduced into the 6'-amino group of the starting compound (X) may preferably be methoxycarbonyl group, ethoxycarbonyl group or benzyloxycarbonyl group. In this way, the 6'-N-alkyloxycarbonylated~ 6'-N-cycloalkyloxycarbonylated or 6'~N-aralkyloxycarbonylated product of the formula (XI) is formed.
The 6' N-alkyloxycarbonyl group, 6'-N-cycloalkyloxy-carbonyl group or 6'-N-aralkyloxycarbonyl group so intro-duced is reductively converted into a methyl group to effect the 6'-N-methylation. This can be achieved by reducing the compound of the formula tXI) with a metal hydride such as ~; lithium aluminum hydride and diborane in an anhydrous organic solvent such as tetrahydrofuran. This reduction may usually be carried out at a temperature o~ 40-90C for lO hours or longer.
This invention ls illustrated with reference to the following Examples to which this invention is not limited.
Examples l to 3 are illustrative of the first and third aspects of this invention, Example 4 illustrative of the - ~i7~16 first and fourth aspects of this invention, Example 5 illustrative of the sixth aspect of this invention, and Examples 6-8 illustrative of the fifth aspect of this invention Example l Synthesis of l-N-[(S)-4-amino-2-hydroxybutyryl]-5,3~,4'-trideoxykanamycin B
(a) 4.36 g (lO mmole) of 5,3',4'-trideoxykanamycin' B
was dissolved in 100 ml of dry dimethylsulfoxide, to which was then added 10.5 g (48 mmole) of zinc acetate [Zn(CH3C02)2 2H20]. The resultant mixture was agitated at ambient temperature for 20 hours to form a complex of 5,3',4'-trideoxykanamycin B with zinc cation. After addi-kion of 1?.~ g (39.5 mmole) of para-methoxybenzyl S-4,6-dimethy~pr'yrimid-2-ylthiocarbonate (product of Kokusan Kagaku X.K., Japan), the resultan~ admixture was agitated at 50C for 7.5 hours to effect the N-p-methoxybenzyloxy-.
carbonylation. The reaction solution obtained was then poured into lO00 ml of water and adjusted to pH ll by ; 20 addition o~ aqueous ammonia to effect the breakdown of the zinc complex, giving a precipitate. The precipitate was filtered off, washed with 500 ml of water and dissolved in 60 ml of a mixed æolvent of chloroform-methanol-17%
aqueous ammonia (50:10:1 by volume). The solution was subjected to chromatography on a column of 500 g of silica gel ~Wako-gel C-200~ developing with the same mixed sol~ent ~ I *trade mark : .

, ~ 1758~

to give 4.1 g (L~4%) of a colorless powder of 3,2',6'-tri-N-paramethoxybenzyloxycarbonyl-5,3',4'-trideoxykanamycin Bo 3.7 g (4 mmole) of the colorless powder was dissolved in 50 ml of dimethylsulfoxide and 0.95 ml (8 mmole) of ethyl trifluoroacetate was added to the solution. The resulting mixture was stirred at room temperature for 5 hours to effect the 3"-N-trifluoroacetylatoin and yield 3,2',6'-tri-N-paramethoxybenzyloxycarbonyl-3"-N-trifluoroacetyl-5,3',4'-trideoxykanamycin B.
(b) To the reaction solution containing the N-protected kanamycin B derivative obtained in step (a) above were added o.6 ml (4.4 mmole) of triethylamine, followed by a solution of 1.9 g (6 mmole) of N-hydroxysuccinimide ester of (S)~4-tert-butoxycarbonylamino-2-hydroxybutyric acid in 20 ml of dioxane. The mixture was agitated at room temper-ature for 19 hours, after which the reaction solution was poured into 500 ml of water to separate a precipitate. The precipitate was filtered off and washed with 100 ml of water to give 10.9 g of a colorless powder. The powder was dissolved in 20 ml of 90% trifluoroacetic acid and the solution was allowed to stand at ambient temperature for 45 minutes to perform removal of the amino-protectlng groups.
The solution was then concentrated to dryness and the residue was taken up in 100 ml of water. The aqueous solution was adjusted to pH 10.5 by addition of aqueous ammonia and stirred at ambient temperature for 20 hours to permit .~

' .: ~

~ 17581 -- 59 ~

removal of the trifluoroacetyl group. The resultant reaction solution was concentrated to a volume of about 20 ml, adjusted to pH 7.5 by addition o~ aqueous ammonia, diluted with 50 ml of water and then passed through a column of 150 ml of Amberlite CG-50 resin (NH4 form, product of Rohm & Haas Co., U.S~A.). The column was washed successively with 750 ml of water and with 500 ml of 0.5 N aqueous ammonia and then eluted with 0.8 N aqueous ammonia. ~he eluate fractions containing the desired product were combined together and concentrated to dryness to give 1.76 g (72%) of 1-N-~(S)-4-amino-2-hydroxybutyryl~-5~3Y,4'-trideoxykanamycin B monocarbonate monohydrate as a colorless powder. Overall yield 32%.
Example 2 -Synthesis of l-N-(3-amino-2-hydroxypropionyl)-5,3'~4'-trideoxykanamycin B
- .
(a) 435.5 mg ~1 mmole) of 5,3'~4'-tridecxykanamycin B
was dissolved in 10 ml of dry dimethylsulfoxide, to which was then added 1.05 g (4.8 mmole) o~ zinc acetate ~Zn(CH3CO2)2 2H2O]. The resulting mixture was agitated at room temperature ~or 23 hours. Thereafter, a solution of 937.3 mg (3.9 mmole) of tert-butyl S-4,6-dimethylpyrimid-2-ylthiocarbonate in 5 ml of dimethylsulfoxide was added thereto and the resulting admixture was stirred at 50C
~or 24 hours to effect the N-tert-butoxycarbonylatlon.
The reaction solution obtained was admixed with 15 ml of *trade mark ...... ,~, . . . . . .

l i75816 water~ adjusted to pH 11 with aqueous ammonia~ followed by addition of 6.4 g of sodium chloride and extraction with ethyl acetate (2 x 15 ml). The ethyl acetate extracts were combined together and concentrated to dryness and the residue was taken up in 6 ml of dimethylsulfoxide. The solution was admixed with 0.125 ml (1 mmole) of ethyl tri-fluoroacetate and the admixture was stirred at ambient temperature for 4 hours to effect the 3"-N-trifluoroacety-lation.
(b) To the reaction solution containing 3,2',6'-tri-N-tert-butoxycarbonyl-3"-N-trifluoroacetyl-5,3',4'-trideoxy-kanamycin B produced in step (a) above were added 0.1 ml (0.7 mmole) of triethylamine and 384 mg (1.05 mmole) of N-hydroxysuccinimide ester of paramethoxybenzyl.oxycarbonyl-isoserine. The resultant mixture was agitated at ambient temperature for 20 hours, after which the reaction solution was admixed with 10 ml of water and extracted with ethyl acetate (2 x 10 ml). The combined extracts were concen-trated to a small volume, followed by addition of 20 ml of 3N hydrochloric acid - 50% methanol. The mixture was stirred at room temperature for 2 hours to perform simultaneous removal of both the tert-butoxycarbonyl and para-methoxybenzyloxycarbonyl groups as the amino-protective ~roups. The resulting reaction solution was adjusted to pH 10 by addition of aqueous ammonia and then stirred at ambient ternperature for 21 hours to permit removal of the ' .
:, ~ ~ 7$~16 trifluoroacetyl group. The reaction solution so obtained was evaporated to a small volume and diluted with water, and the resulting aqueous solution was passed through a column of 25 ml of Diaion WK-lOS (NHLi~ form, product of Mitsubishi Kasei K.K., Japan). The column was washed with 125 ml of water and then eluted with 0.4 N aqueous ammonia.
The eluate fractions containing the desired product were combined together and concentrated to dryness to give 257 mg of 1-N-(3-amino-2-hydroxypropionyl)-5,3',4'-trideoxykanamycin B monocarbonate as a colorless powder.
Qverall yield 42%.
Example 3 Sy_thesis of l-N-[(S?-4-amino-2-hydroxybutyryl]-5 ? 3 ~ ~ 4'?6"-tetradeo'xykanamycin B
(a) 419.5 mg (0.75 mmole) of 5,3',41,6"-tetradeoxy-kanamycin B dicarbonate monohydrate was dissoIved in 10 ml of dry dimethylsul~oxide, to which was then added 1.05 g (4. 8 mmole~ of zinc acetate ~Zn(CH3C02)2 2H20~ and the mixture was agitated at room temperature for 18 hours.
Thereafter, a solution of' 1.44 g (6.0 mmole) of tert-butyl S-4,6-dimethylpyrimid-2-ylthiocarbonate' in 5 ml of' dimethylsulf`oxide was added thereto and the resulting admixture was stirred at 50C for 25 hours. The reaction solution obtained was admixed with 15 ml of water, adjusted to pH 11 with aqueous ammonia and extracted with ethyl acetate (2 x 15 ml). ~he aqueous layer was admixed with *trade mark . .. . . .

~ ~7~6 6.4 g of sodium chloride and further extracted with 20 ml of ethyl acetateO The whole ethyl acetate extracts were combined together and concentrated to dryness and the residue was taken up in 6 ml of dimethylsulfoxide. The solution was admixed with 0.125 ml (1 mmole) of ethyl trifluoroacetate and the admixture was stirred at ambient temperature for 4 hours.
(b) To the reaction solution containing 3,2',6'-tri-N-tert-butoxycarbonyl-3"-N-tri~luoroacetyl-5,3',4',6"-tetra-deoxykanamycin B produced in step (a) above were added0.1 ml (0.7 mmole) of triethylamine and 399.4 mg (1.05~
mmole) of N-hydroxysuccinimide ester of (S)-4-p-methoxy-benzyloxycarbonylamino-2-hydroxybutyric acid. The resultant mixture ~as agitated at ambient temperature for 18 hours, after whlch the reaction solution was admixed with 10 ml of water and extracted with ethyl acetate ~2 x 10 ml).
The combined extracts were concentrated to a small volume, followed by addition of 20 ml of 3 N hydrochloric acid -50% methanol. The mixture was stirred at room temperature for 2 hours to perform removal of both the tert-butoxy-carbonyl and para-methoxybenzyloxycarbonyl groups. The resulting reaction solution was ad~usted to pH 10 by addition of aqueous ammonia and then stirred at ambient temperature for 20 hours to permit removal of the tri-fluoroacetyl group. The reactlon solution so obtained wasevaporated to a small volume and diluted with water, and . .~

~ ~7~8~1 - 63 ~

the resulting aqueous solution was passed through a column of 25 ml of Diaion WK-10S (NH4 form). The column was washed with 125 ml of water and then eluted with 0.32 N aqueous ammonia. The eluate fractions containing the desired product were combined together and concentrated to dryness to give 303 rng of 1-N-[(S)-4-amino-2-hydroxybutyryl)-5,3',4',6"-tetradeoxykanamycin B dicarbonate as a colorless powder. Overall yield 63%.
Example 4 Synthesis of 5~3',4',6"-tetradeoxykanamycin B
(a) Preparation of 1,3,2',6',3"-penta-N-ethoxycarbonyl-; 3~,41-dideoxykanamycin B
4.64 g (10.3 mmole) of 3~,4'-dideoxykanamycin B was ~ disolved in a mixture-of 45 ml. of water and 45 ml of ; 15 methanol, to which was then added 8 g (95.2 mmole) of sodium bicarbonate, followed by slow addition of 7.2 ml (75.6 mmole) of ethyl chloroformate ur,der ice-cooline.
The resultant mixture was stirred at room temperatu:re for 18 hours to effect the N-ethoxycarbonylation. The reaction solution obtained was admixed with 500 ml of water to æeparate a preoipitate. rrhe latter was filtered off and washed with water to af~ord 6.49 g (78%) of a colorless powder of the title compound.
tb) Preparation of 1,3,2',6',3"-penta-N-ethoxycarbonyl-41l,6l'-0-isopropylidene-3',4~-dideoxykanamycin B
4.83 g (5.95 mmole) of the product obtained in step ~
! ;; *trade mark "``" 5 ~75~1~
- 64 - ~

(a) above was dissolved in 50 ml of dimethylformamlde, and to the resulting solution were added 30 mg (0.16 mmole)~of ; p-toluenesulfonic acid and 1.1 ml (9.0 mmole~) of~2,2-dimethoxypropane. The resulting mixture was agitated at :
ambient temperature for 25 hours (to effect the 4!l,6ll-o- ;
isopropylidenation), after which the reaction solut-ion~was~
admixed with 1 ml~(7~.~2~ mmole) of triethylamine and then concentrated to dryness to give~5.1 g (100%) of the title compound as a pale yellow~powder.
10~ ~ (c)~ Preparatlon of~l,3,2',;6'~,3"-penta-N-ethoxYcarbonyl~
4",6"-0-1sopropylidene-2"-0-benzoyl-3~ 4'-dideoxy~
kanamycin~B~
; 5.1 g (6~.0~mmole) of the~product from step~(b) above was~dissolved ln~75~ml~o~pyridine,~to~which was~then~added~
15~ ;ml (8.6 mmole);~of benzoyl~ohloride, and~the mlxture~was~
agitated~at~r~oom témp~erature~f~or~5 hours to ef~ect~the~
2"-0-benzoyl`ation. The~react~ion~solution;so obtained~was ;admixed with~10 ~ of~water, stirred;~at~room temp~erature~
;and ~then concentrated~to dryne~ss.~ The residue w~s~takén 2n~ up~ in 250~ml;or c~loroform~and~the~s~lution~was~washed~
successively with`lOO ml~of 0.2 N;hydrochloric acld~and 2 x 100 ml of~sat~urated aqueous~sodium bioarbonate~solutlon~
The chlorofo~r~ lay~èr~was sep~arated,;dried over anhy;droua sodium sulfate and~concentratéd to dryness to ~ive 5.7 g (99%) o~ the title compound;~as a pale yellow powder.

':: : `

~ ~758~6 (d) Preparation of 1,3,2 t ~ 6',3" penta-N-ethoxycarbonyl-2"-0-benzoyl-3',4l-dideoxykanamycin B
5.3 g (5.5 mmole) of the product from step (c) above was dissolved in 80 ml of a mixture of acetic acid-methanol-water (2:1:1 by volume) and the resultant solution was . allowed to stand at ambient temperature for 21 hours and then concentrated to dryness to yield 4.3 g (97%) of the title compound as a pale yellow powder.
: (e) Preparation o~ 113,2',6',3~'-penta-N-ethoxycarbonyl-.
~ 2"-0-be~zoyl-6"-0-tosyl-3',4'-dideoxykanamycin B
. 1.5 g (1.63 mmole) of the product obtained in step .
. . (d~ above was dissolved in 28 ml of pyridine, to which was ~: then added 374 mg (1.96 mmole) Or paratoluenesulfonyl - . chloride~ and the mlxture was agitated at room temperature for 28 hours to effect the 6"-0-tosylation. The resulting reaction solution was concentrated to dryness, the powdery residue (2.3 g) was taken up in 12.5 ml of dichlorornethane and the solution obtained was subjected.to column chromato-graphy on silica gel (Wako-gel C-200, 200 g). The column was washed with 1000 ml of dichloromethane-ethanol (60:1) and then developed with dichloromethane-ethanol (50:1) to give 1.0 g (60%) of a colorless powder of the title compound.
(f) Preparation of 1,3,2',6',3"-penta-~-ethoxycarbonyl-2"--0-benzoyl-6"-iodo-3',4 ~ -dideoxykanamycin B
900 mg (0.84 mmole) of the product from step (e) *trade mark ~, .

~ 175~1 above was dissolved in 18 ml of dimethylformamide, followed by addition of 12.6 g ~84 mmole) of sodium iodide and agitation at 95C for two hours to effect the 6~'-iodination.
The reaction solution obtained was poured into 250 ml of water, and the precipitate deposited was filtered off and then dissolved in 100 ml of chloroform. The chloroform ; solution was washed with 100 ml of 20% aqueous sodium thiosulfate and with 100 ml of saturated aqueous sodium chloride. m e chloroform layer separaked was dried over anhydrous sodium sulfate and concentrated to dryness ko - give 817 mg (95%) of khe title compound as a colorless powder.
(g) Preparation of 1~3,21,6',3'r-penta-N-ethoxycarbonyl-?"-0-benzoyl-3',4' 9 61'-trideoxykanamycin B
773 mg (0.75 mmole) of the product from step (f) above was dissolved in 20 ml of dioxane, to which was then added a small amount of Raney Nickel W-2, and the mixture was hydrogenated under a hydrogen pressure of 3.6 kg/cm2 ~or 23.5 hours using a Parr apparatus. The resultant reaction solution was filtered to remove the catalyst and then concentrated to dryness to af~ord 655 mg (97%) of a colorless powder o~ khe title compound.
th) Preparation o~ 1,3,2',6'~3"-penta-N-ethoxycarbonyl-21',4'l-dl-0-benzoyl-3',4',6'--trideoxykanamycin B
622 mg ( a . 69 mmole) of the product obtained in step (g) above was dissolved in 30 ml of pyridine, followed by ' - *trade mark I 175~s~6 addition of 0.1 ml (o.86 mmole) of benzoyl chloride and agitation of the mixture at room temperature for 25 hours to effec-t the 4"-O-benzoylation. The resultant reaction solution was concentrated to dryness and the residue was taken up in 50 ml of chloroform. The solution was washed successively with 10% aqueous potassium bisulfate (2 x 30 ml), saturated aqueous sodium bicarbonate (2 x 30 ml) and saturated aqueous sodium chloride (l x 30 ml), then ; dried over anhydrous sodium sulfate and concentrated to dryness to give 663 mg (96%) of the title compound as a colorless powder.
(i) Preparation of 1,3,2',6',3l'-penta-N-ethoxycarbonyl-2",4"-di-0-benzoyl-5-chloro-3',4',6"-trideoxy-: kanamycin B
600 rng (0.6 mmole) of the product from step (h) above was dissolved in 12 ml of pyridine, to which was then added 0.1 ml (1.24 mmole) of sulfuryl chloride under ice-cooling, and the mixture was stirred at ambient temper-ature for 18 hours to effect the 5-chlorination. The reaction solution thus obtained was admixed with lO0 ml of water and extracted with 60 ml of chloroform. The chloroform extract was washed successively with 60 ml of 10% aqueous potassium bisulfate, 60 ml of saturated aqueous sodium bicarbonate and60 ml of saturated aqueous sodium chloride, then dried over anhydrous sodlum sulfate and concentrated to dryness. The resultant powdery resldue (572 mg) was taken up in 5 ml of dichloromethane and chromatographed on a column of silica gel (Wako-gel C-200, 50 g). The column was washed with 500 rnl of dichloromethane and developed with a mixture of dichloromethane-ethanol ~100:1~ to give 356 mg (58%) of a colorless powder of the title compound.
(;) Preparation of ls3,2',6',3''-penta-N-ethoxycarbonyl-2",4"-di-0-benzoyl-5,3',4',6~'-tetradeoxykanamycin B
308 mg (0.13 mmole) of the product from step (i) above was dissolved in 5 ml of dioxane, to which was then added a small amount of Raney Nickel W-2, and the mixture was hydrogenated under a hydrogen pressure of 3.6 ; kg/cm2 for 23.5 hours using a Parr apparatus to effect the dechlorination. The resultant reaction solution was filtered to remove the catalyst and then concentrated to .
~ 15 dryness to afford-295 mg (100%) of a colorless powder of ~:
the title compound.
k) Preparation of 5,3',4',6"-tetradeoxykanamycin B
120 mg (0.12 mmole) of the product obtained in step (j~ above was dissolved in a mixture o~ 1 ml of dioxane and 1 ml of water, to which was then added 400 mg (1.27 mmole) of barium hydroxide [Ba(OH2) 8H20], and the resultant mixture was subjected tothe deprotection by heating at 110C for 15 hours under re~lux. Thereafter, gaseous carbon dioxide was passed into the reaction solution to precipitate barium carbonate, which was filtered off. The filtrate was admixed with 30 ml of water and passed through *trade mark :

.

, . .: ~ .

~ ~7~i816 a column of 20 ml of Amberlite CG-50 (NH4 form, product of Rohm & Haas Co., U.S.A.). The column was washed with 100 ml of water and 75 ml of 0.1 N aqueous ammonia and then eluted with 0.3 N aqueous ammonia.- The eluate fractions containing the desired product were combined together and concentrated to dryness to give 19.5 mg (29%) o~ 5,3',4l,6~'-tetradeoxykanamycin B dicarbonate monohydrate as a colorless powder.
Example 5 Synthesis o~ 5,3',4'-trideoxy-6'-N-methylkanamycin B
~a)- 4.0 g (9.18 mmole) of 5,3',4'-trideoxykanamycin B
was dissolved in a mixture of 40 ml of water and 40 ml of methanol, to which was then added a solution of 5.8 ml ~9.18 mmole) o~ triethylamine and 2.72 g (11.02 mmole) of 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile (commercially available under the trade-mark BOC-ON from Aldrich Co., U.S.A.) in 40 ml of methanol. The resultant mixture was agitated at room temperature for 3 hours, after which the reaction solution containing 6'-N-tert-butoxy-carbonyl-5,3',4'-trideoxykanamycin B formed was admixed with 2 ml o~ 17% aqueous ammonia and concentrated to dryness. The residue was taken up ln 100 ml of water and the solution was ad~usted to pH 7.4 with 6 N hydrochloric acid, washed with 50 ml of ethyl ether and then passed through a column (20 mm in inner diameter) of 100 ml of Amberlite CG-50 (NH4 form, product of Rohm & Haas Co~, *trade mark .

~ 1'7~16 U.S.A.). The column was washed with 300 ml of water and 150 ml o~ 0.1 M aqueous ammonia and then eluted with 0.2 M
aqueous ammonia. The eluate was collected in 5 ml-fractions ~ and the fractions No. 11-24 were combined together and; 5 concentrated to dryness to give 2.1 g (42.5%) of 6'-N-tert-butoxycarbonyl-5,3'~4'-trideoxykanamycin B. Concentration to dryness of the fractions No. 26-33 combined recovered 1.42 g (35.6%) of unreacted 5~3',4t-trideoxykanamycin B.
(b) 1.86 ~ (3.45 mmole) of the 6'-N-tert-butoxycarbonyl-553',4t-trideoxykanamycin B obtained just above was dissolved in 60 ml of dry tetrahydrofuran, followed by addit~on of 1.31 g (34.5 mmole) of lithium aluminium hydride and heating at 80C for 20 hours under reflux.
The resulting reaction mixture was added dropwise into 200 ml of water to separate a precipitate, which was filtered off. The filtrate was evaporated to r-emove the~
tetrahydrofuran and then adjusted to pH 6.5 by addition of hydrochloric acid. The solution so obtained was passed through a column (12 mm in inner diameter) Or 30 ml of Amberlite CG-50 (NH4 ) and the column was washed with 150 ml of water and eluted successively with Q.2 M a~ueous ammonia (150 ml), 0.3 M aqueous ammonia (150 ml) and 0.4 M
aqueous ammonia. The eluate was collected in 6 ml-fractions and the ~ractions No. 11-17 were combined together and concentrated to dryness to recover 740 mg (3g.9%) of unreacted 6'-N-tert-butoxycarbonyl-5,3',4'-trideoxykanamycin ;~i *trade mark , ., "~,s~ I .

.

~ ~75~16 B. ~hile~ the ~ractions No. 37-55 were likewise concen-trated to dryness to a~ford 592 mg (32.4%) o~ the title compound 5,3',4'-trideoxy-6'-N-methylkanamycin B.
Example 6 Synthesis of l-N-~(S)-4-amino-2-hydroxybutyryl]-5,3'~4'-trideox~-6'-N-methylkanamycin B
583 mg (1.10 mmole) of the 5~3',4l-trideoxy-6 t -N-methylkanamycln B prepared as described in ~xample 5 was dissolved in lQ ml o~ 90% aqueous dimethylsul~oxide, to which was then added 1.16 g (5.28 mmole) o~ ~inc acetate ~Zn(CH3CO2)2 2H2O]. The mixture was stirred at ambient temperature ~or 20 hours, followed by addition of a solution of 1.06 g (4.29 mmole) of 2-(tert~butoxycarbonyloxyimino)-2-phenylacetonitrile in 5 ml of dimethylsulfoxide and ~urther agitation at 50C for 6 hours to effect the N tert-butoxycarbonylation. The resulting reaction solution was admixed with 2 ml of 17% aqueous ammonia and then with 100 ml o~ water and washed with 50 ml of ethyl ether. The aqueous layer separated was adjusted to pH 11 with 17%
aqueous ammonia and admixed with 2 g o~ sodium chloride, and the resulting solution was extracted with ethyl acetate (3 x 100 ml). The ethyl acetate extracts combined were dried over anhydrous sodium sulfate and concentrated to dryness. The residue was chromatographed on a column (20 mm in inner diameter) of 50 g of silica gel (Wako-gel C-200 manu~actured by Wako Junyaku K.K., Japan) using as the *trade mark `

.. .

eluent a mixture of chloroform-methanol-conc. aqueous ammonia (30:10:1 by volume). The eluate was collected in 10 ml-fractions and the fractions No. 25-50 were combined together and concentrated ~o dryness to give 607 mg (73.6%) of 3,2l,6'-tri-N-tert-butoxycarbonyl-5,3',4'-trideoxy-6'-N-methylkanamycin B.
590 mg (0.787 mmole) of the product obtained just above was dissolved in 10 ml of dimethylsulfoxide, and to the solution obtained was added 0.14 ml (1.18 mmole) of ethyl trifluoroacetate. The admixture was stirred at room temperature for 1.5 hours to effect the 3'~-N-trifluoro-acetylation. The resultant reaction solution containing 3,2',6'-tri-N~tert-butoxycarbonyl-3"-N-trifluoroacetyl-5,3',4'-trideoxy-6'-N-methylkanamycin B produced was admixed with both 0.16 ml (1.18 mmole) of triethylamine and 420 mg (1.18 mmole) of N-hydroxysuccinimide ester o~
(S)-4-p-methoxybenzyloxycarbonylamino-2-hydroxybutyric acid dissolved in 4 ml of tetrahydrofuran and the admixture was agitated at room temperature for 4 hours to effect the l-N-acylation. Subsequently, 100 ml of water was added to the reaction solution, which was then extracted with ethyl acetate (2 x 100 ml). The extracts combined were dried over anhydrous sodium sulfate and concentrated to dryness to afford the l-N-acylated product in the form of the amino-protected derivative thereof.
This 1-N-aoylated product so obtained was dissolved . ., ~ ~7581 in 10 ml of 90% aqueous trifluoroacetic acid and the solution was agitated at ambien~ temperature for 5 hours to permit the removal of the tert-butoxycarbonyl and p-methoxybenzyloxycarbonyl groups and then the reaction solutîon was concentrated to dryness. The residue was taken up in 30 ml of water and the solution was adjusted to pH 10 with 17% aqueous ammonia, followed by stirring at room temperature for 18 hours to permit the removal of the trifluoroacetyl group. The reaction solution thus obtained was adJusted to pH 7.5 by addition of 6 N
hydrochloric acid and passed through a column (13 mm in ~nner diameter) of 20 ml of Amberlite CG-50 (NH4 form).
The column was washed with 100 ml of water and eluted successively with 160 ml of 0.5 M aqueous ammonia and 100 ml of 0.8 M aqueous ammonia. The eluate was collected in 4 ml-fractions and the fractions No. 2i-62 were combined together and concentrated to dryness to yield 346 rn~ (71.8%) o~ the titled compound, l-N-[(S)-4-amino-2-hydroxybutyryl]-5,3',4'-trideoxy-6'-N-methylkanamycin B in the form of its monocarbonate.

Synthesis of l-N-~3-amino-2-hydroxypropiony~-5~3l~4 trideoxy-6'-N~methylkanamycin B
102 mg (0.136 mmole) of the 3,2'~6'-tri-N-tert-butoxycarbonyl-5,3',4'-trideoxy-6'-N-methylkanamycin B
prepared as in Example 6 was dissolved in 3 ml of .

*trade mark I ~75 dimethylsulfoxide, and to the resultant solution was added 0.02 ml (0.204 mmole) of ethyl trifluoroacetate. The mixture was stirred at room temperature for one hour. The resultan-t reaction solution containing 3,2',6'-tri-N-tert-butoxycarbonyl-3"-N-trifluoroacetyl-5,3',4'-trideoxy-6'-N-methylkanamycin B produced was admixed with both 0.03 ml (0.204 rnmole) of triethylamine and 75 mg (0.204 mmole) of N-hydroxysuccinimide ester of 3-p-methoxybenzyloxycarbonyl-amino-2-hydroxypropionic acid dissolved in 0.5 ml of tetra-hydrofuran, and the admixture was agitated at roomtemperature for 7 hours to effect the l-N-acylation.
Subsequently, 10 ml of water was added to the reaction solution, which was then extracted with ethyl acetate (2 x 10 ml). The extracts combined were dried over anhydrous sodium sulfate and concentrated to dryness to afford 136 mg of the l-N-acylated product in the form of the amino-protected derivative thereof.
This l-N-acylated product was dissolved in 3 ml of 90% aqueous trifluoroacetic acid and the solution was agitated at ambient temperature for 2 hours to permit the removal of the tert--butoxycarbonyl and ~-methoxybenzyloxy-carbonyl groups, and then the reaction solution was con-centrated to dryness. ~he residue was taken up in 10 ml of water and the solution was ad~usted to pH 10 with 17~
aqueous ammonia, ~ollowed by stirring at roorn temperature for 16 hours to permit the removal of the tri~luoroacetyl ~ 1i7$8~6 group. The reaction solution thus obtained was ad~usted to pH 6.4 by addition of 6 N hydrochloric acid and passed through a column (11 mm in înner diameter) of 10 ml of Amberlite CG-50 (NH4+ form). The column was washed with 30 ml o~ water and 30 ml of 0.2 M aqueous ammonia and then eluted with 0.5 M aqueous ammonia. The eluate was collected in 1 ml fractions and the fractiorls No. 4-7 were combined together and concentrated to dryness to yield 3801 mg (45.4%) of the desired l-N-[3-amino-2-hydroxypropionyl]-5,3~94'-trideoxy-6'-N-methylkanamycin B in the form of its mono-carbonat e .
Example 8 Synthesis of l-N-[(S)-5-amino-?-hydroxyvaleryi]=5~3',4 trideoxy-6'-N-methylkanamycin B
. , The same procedures as described in Example 7 were - repeated but using 76 mg (0.204 mmolej of N-hydroxysuccin-imide ester of ~S)-5-p-methoxybenzyloxycarbonylamino-2-: hydroxyvaleric acid in place of the 3-_-methoxybenæyloxy-carbonylamino-2-hydroxy-propionic acid N-hydroxysuccinimide ester to be reacted with the 3,2',6'-tri-N-tert-butoxy-carbonyl-3l'-N-trifluoroacetyl-5,3',4'-trideoxy-6'-N-methylkanamycin B.
After the elution of the Amberlite CG-50 column, the eluate .~ractions No. 11-18 were combined together and concentrated to dryness to give 47.2 mg (53.8%) of the title compound (rnonocarbonate).

- *trade mark

Claims (24)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A process for preparing a compound of general formula:

(I) wherein:

R represents a group selected from H and -OH;
R1 represents a group selected from H and an .alpha.-hydroxy-.omega.-aminoalkanoyl of general formula -CO-CH(OH)-(CH2)n-NH2, wherein n represents an integer of 1, 2 or 3; and R2 represents a group selected from H and -CH3;
with the proviso that when R represents H, R2 does not represent -CH3; and when R represents -OH, R1 and R2 do not, simultaneously, represent H;
said process comprising:
(A)when R, R1 and R2 represent H:
(a)protecting the 4"-OH group of a penta-N-protected and 2"-0-protected derivative of 3',4',6"-trideoxykanamycin B
to produce a compound of general formula:

Claim 1...cont'd.(2) (VIII') wherein A represents H and B represents a mono-valent NH2-protecting group; or A and B, when taken together, represent a di-valent NH2-protecting group; and D represents an OH-protecting acyl group;
(b) reacting the compound of general formula (VIII') with sulfuryl chloride to replace the 5-OH group thereof with Cl to produce the corresponding 5-Cl derivative;
(c) reaucing the 5-Cl derivative to remove the 5-Cl group;
and (d) removing the remaining five NH2-protecting groups and the two OH-protecting groups to produce the desired compound, 5,3',4',6"-tetradeoxykanamycin B;
(B) when R and R2 reprçsent H, and R1 represents the .alpha.-hydroxy-.omega.-aminoalkanoyl group:
(e) acylating the 1-NH2 group of 5,3',4',6"-tetradeoxykanamycin B or a partially amino protected derivative thereof of general formula:

Claim 1...cont'd.(3) (VI'a) wherein A represents H and at least one B represents a mono-valent NH2-protecting group, the remaining B(s) representing H; or at least one pair of A and B, when taken together, represent a di-valent NH2-protecting group, the remaining A(s) and B(s) representing H; wherein A and B
represent NH2-protecting groups independent of each other;
by reaction with an .alpha.-hydroxy-.omega.-aminoalkanoic acid or an NH2-protected derivative thereof of general formula:

(VII) wherein A' represents H and B' is selected from H and a mono-valent NH2-protecting group; or A' and B', when taken together, represent a di-valent NH2-protecting group; and n is as defined above; or a functional equivalent of the compound of general formula (VII), to produce a 1-N-acylated product of general formulae:

Claim 1...cont'd.(4) (II'a) or (II"a) wherein A, B, A', B' and n are as defined above; and (f) removing the remaining NH2-protecting group(s) to produce the desired compound, 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4',6"-tetradeoxykanamycin B;

Claim 1...cont'd.(5) (C) when R represents -OH, R1 represents the a-hydroxy-.omega.-aminoalkanoyl group and R2 represents H:
(g) repeating steps (e) and (f) with 5,3',4'-trideoxy-kanamycin B or a partially NH2-protected derivative thereof of general formula:

(VI 'b) wherein A and B are as defined above, as the starting material, to produce the desired compound, 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxykanamycin B;
(D) when R represents -OH, R1 represerts the .alpha.-hydroxy-.omega.-aminoalkanoyl group and R2 represents -CH3:
(h) repeating steps (e) and (f) with 5,3',4'-trideoxy-6'-N-methylkanamycin B or a partially NH2-protected derivative thereof of general formula:

(VI'c)
1. Claim 1...cont'd.(6) wherein A and B are as defined above, as the starting material, to produce the desired compound, l-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxy-6'-N-methylkanamycin B;
   (E) when R represents -OH, R1 represents H and R2 represents -CH3:
   (i) introducing a group selected from alkyloxycarbonyl, cycloalkyloxycarbonyl and aralkyloxycarbonyl at the 6'-NH2 group of 5,3',4'-trideoxykanamycin B to produce a compound of general formula:
   
   (XI) wherein R3 represents a group selected from (C1-C6)alkyl, (C3-C6)cycloalkyl and aralkyl, including phenyl(C1-C4)alkyl, including benzyl; and (j) reducing the compound of general formula (XI) with a metal hydride in an anhydrous organic solvent to produce the desired compound, 5,3',4'-trideoxy-6'-N-methylkanamycin B;
   and (F) when required, producing a pharmaceutically acceptable acid-addition salt of the compounds of steps (A) to (E).
2. 2. A compound of general formula (I), as defined in claim 1, and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 1 or an obvious chemical equivalent thereof.
3. 3. A process for preparing 5,3',4',6"-tetra-deoxykanamycin B, comprising:
   (a') protecting the 4"-OH group of a penta-N-protected and 2"-O-protected derivative of 3',4',6"-trideoxykanamycin B to produce a compound of qeneral formula:
   
   (VIII') wherein A represents H and B represents a mono-valent NH2-protecting group; or A and B, when taken together represent a di-valent NH2-protecting group; and D
   represents an OH-protecting acyl group;
   (b') reacting the compound of general formula (VIII') with sulfuryl chloride to replace the 5-OH group thereof with Cl to produce the corresponding 5-Cl derivative;
   (c') reducing the 5-Cl derivative to remove the 5-Cl group;
   (d') removing the remaining five NH2-protecting groups and the two OH-protecting groups to produce the desired compound, 5,3',4',6"-tetradeoxykanamycin B; and (k) when required, producing a pharmaceutically acceptable acid-addition salt.
4. 4. 5,3',4',6"-Tetradeoxykanamycin B and a pharma-ceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 3 or an obvious chemical equivalent thereof.
5. 5. A process for preparing 5,3',4'-trideoxy-6'-N
   methylkanamycin B, comprising:
   (i') introducing a group selected from alkyloxycarbonyl, cycloalkyloxycarbonyl and aralkyloxycarbonyl at the 6'-NH2 group of 5,3',4'-trideoxykanamycin B to produce a compound of general formula:
   
   (XI) wherein R3 represents a group selected from (C1-C6)alkyl, (C3-C6)cycloalkyl and aralkyl, including phenyl(C1-C4) alkyl, including benzyl;
   (j') reducing the compound of general formula (XI) with a metal hydride in an anhydrous organic solvent to produce the desired compound,5,3',4'-trideoxy-6'-N-methylkanamycin B; and (k) when required, producing a pharmaceutically acceptable acid-addition salt.
6. 6. 5,3',4'-Trideoxy-6'-N-methylkanamycin B and a pharma-ceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 5 or an obvious chemical equivalent thereof.
7. 7. A process for preparing l-N-(.alpha.-hydroxy-.omega.-amino-alkanoyl)-5,3',4',6"-tetradeoxykanamycin B, comprising:
   (e') acylating the 1-NH2 group of 5,3',4',6"-tetradeoxykanamycin B or a partially amino protected derivative thereof of general formula:
   
   (VI'a) wherein A represents H and at least one B represents a mono-valent NH2-protecting group, the remaining B(s) representing H; or at least one pair of A and B, when taken together, represent a di-valent NH2-protecting group, the remaining A(s) and B (s) representing H; wherein A and B represent NH2-protecting groups independent of each other; by reaction with an .alpha.-hydroxy-.omega.-aminoalkanoic acid or an NH2-protected deriyative thereof of general formula:
   
   (VII) wherein A' represents H and B' is selected from H and a mono-valent NH2-protecting group; or A' and B', when taken together, represent a di-valent NH2-protecting group; and n represents an integer of 1, 2 or 3; or a functional equivalent of the compound of general formula (VII), to produce a 1-N-acylated product of general formulae:
   
   (II'a) or (II"a) wherein A, B, A', B' and n are as defined above;
   (f') removing the remaining NH2-protecting group(s) to produce the desired compound, 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4',6"-tetradeoxykanamycin B; and (k) when required, producing a pharmaceutically acceptable acid-addition salt.
8. 8. 1-N-(.alpha.-Hydroxy-.omega.-aminoalkanoyl)-5,3',4',6"-tetradeoxykanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 7 or an obvious chemical equivalent thereof.
9. 9. A process as defined in claim 7, wherein the compound of general formula (VII), n represents 2; and the (S) somer is prepared.
10. 10. 1-N-[(S)-4-Amino-2-hydroxybutyryl]-5,3',4',6"-tetradeoxykanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 9 or an obvious chemical equivalent thereof.
    11. A process for preparing 1-N-(.alpha.-hydroxy-.omega.-amino-alkanoyl)-5,3',4'-trideoxykanamycin B, comprising:
    (g') acylating the 1-NH2 group of 5,3',4'-trideoxykanamycin B
    or a partially amino protected derivative thereof of general formula:
    
    (VI'b) wherein A represents H and at least one B represents a mono-valent NH2-protecting group, the remaining B(s) Claim 11...cont'd.(2) representinq H; or at least one pair of A and B, when taken together, represent a di-valent NH2-protecting group, the remaining A(s) and B(s) representing H;
    wherein A and B represent NH2-protecting groups independent of each other; by reaction with an .alpha.-hydroxy-.omega.-aminoalkanoic acid or an NH2-protected derivative thereof of general formula:
    
    (VII) wherein A' represents H and B' is selected from H and a mono-valent NH2-protecting group; or A' and B', when taken together, represent a di-valent NH2-protecting group; and n represents an integer of 1, 2 or 3; or a functional equivalent of the compound of general formula (VII), to produce a 1-N-acylated product of general formulae:
    
    (II'a) or
11. Claim 11...cont'd.(3) (II"a') wherein A, B, A', B' and n are as defined above;
    removing the remaining NH2-protecting group(s) to produce the desired compound, 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxykanamycin B; and (k) when required, producing a pharmaceutically acceptable acid-addition salt.
12. 12. 1-N-(.alpha.-Hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxy-kanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 11 or an obvious chemical equivalent thereof.
13. 13. A process as defined in claim 11, wherein the compound of general formula (VII), n represents 1.
14. 14. 1-N-(3-Amino-2-hydroxypropionyl)-5,3',4'-trideoxy-kanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 13 or an obvious chemical equivalent thereof.
15. 15. A process as defined in claim 11, wherein the compound of general formula (VII), n represents 2; and the (S) isomer is prepared.
16. 16. 1-N-[(S)-4-Amino-2-hydroxybutyryl]-5,3',4'-trideoxykanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 15 or an obvious chemical equivalent thereof.
    17. A process for preparing 1-N-(.alpha.-hydroxy-.omega.-amino-alkanoyl)-5,3',4'-trideoxy-6'-N-methylkanamycin B, comprising:
    (h') acylating the 1-NH2 group of 5,3',4'-trideoxy-6'-N-methylkanamycin B or a partially amino protected derivative thereof of general formula:
    
    (VI'c) wherein A represents H and at least one B represents a mono-valent NH2-protecting group, the remaining B(s) representing H; or at least one pair of A and B, when taken together, represent a di-valent NH2-protecting group, the remaining A(s) and B(s) representing H;
    wherein A and B represent NH2-protecting groups independent of each other; by reaction with an .alpha.-hydroxy-.omega.-aminoalkanoic acid or an NH2-protected derivative thereof of general formula:
    
    Claim 17...cont'd.(2) wherein A' represents H and B' is selected from H and a mono-valent NH2-protecting group; or A' and B', when taken together, represent a di-valent NH2-protecting group; and n represents an integer of 1, 2 or 3; or a functional equivalent of the compound of general formula (VII), to produce a 1-N-acylated product of general formulae:
    
    (II'a") or (II"a")
17. Claim 17...cont'd.(3) wherein A, B, A', B' and n are as defined above;
    removing the remaining NH2-protecting group(s) to produce the desired compound, 1-N-(.alpha.-hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxy-6'-N-methylkanamyccin B;
    and (k) when required, producing a pharmaceutically acceptable acid-addition salt.
18. 18. 1-N-(.alpha.-Hydroxy-.omega.-aminoalkanoyl)-5,3',4'-trideoxy-6'-N-methylkanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 17 or an obvious chemical equivalent thereof.
19. 19. A process as defined in claim 17, wherein the compound of general formula (VII), n represents 1.
20. 20. 1-N-(3-Amino-2-hydroxypropionyl)-5,3',4'-trideoxy--6'-N-methylkanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 19 or an obvious chemical equivalent thereof.
21. 21. A process as defined in claim 17, wherein the compound of general formula (VII), n represents 2; and the (S) isomer is prepared.
22. 22. 1-N-[(S)-4-Amino-2-hydroxybutyryl]-5,3',4'-trideoxy-6'-N-methylkanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 21 or an obvious chemical equivalent thereof.
23. 23. A process as defined in claim 17, wherein the compound of general formula (VII), n represents 3; and the (S) isomer is prepared.
24. 24. 1-N-[(S)-5-Amino-2-hydroxyvaleryl}-5,3',4'-trideoxy-6'-N-methylkanamycin B and a pharmaceutically acceptable acid-addition salt thereof, when prepared by the process defined in claim 23 or an obvious chemical equivalent thereof.